<?xml version="1.0"?>
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.1d1" xml:lang="en" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SMM</journal-id>
      <journal-id journal-id-type="hwp">spsmm</journal-id>
      <journal-id journal-id-type="nlm-ta">Stat Methods Med Res</journal-id>
      <journal-title-group>
        <journal-title>Statistical Methods in Medical Research</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0962-2802</issn>
      <issn pub-type="epub">1477-0334</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage UK: London, England</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.1177/0000000000000000</article-id>
      <article-id pub-id-type="publisher-id">10.1177_0000000000000000</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>test-Response-adaptive designs for continuous treatment responses in phase III clinical trials: A review</article-title>
        <alt-title alt-title-type="left-running-head">journal title</alt-title>
        <alt-title alt-title-type="right-running-head">author nameauthor name</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Biswas</surname>
            <given-names>Atanu</given-names>
          </name>
          <xref ref-type="aff" rid="aff1-0000000000000000">1</xref>
          <xref ref-type="corresp" rid="corresp1-0000000000000000">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Bhattacharya</surname>
            <given-names>Rahul</given-names>
          </name>
          <xref ref-type="aff" rid="aff2-0000000000000000">2</xref>
          <xref ref-type="corresp" rid="corresp2-0000000000000000">2</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-0000000000000000"><label>1</label>Applied Statistics Unit, Indian Statistical Institute, Kolkata 700108, India</aff>
      <aff id="aff2-0000000000000000"><label>2</label>Department of Statistics, West Bengal State University</aff>
      <author-notes>
        <corresp id="corresp1-0000000000000000">Address for correspondence: Atanu Biswas, Applied Statistics Unit, Indian Statistical Institute, 203 B. T. Road, Kolkata 700108, India<email>atanu@isical.ac.in</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <day>00</day>
        <month>00</month>
        <year>0000</year>
      </pub-date>
      <volume>00</volume>
      <fpage>00</fpage>
      <lpage>00</lpage>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2014</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
      </permissions>
      <abstract>
        <p>A variety of response-adaptive randomisation procedures have been proposed in literature assuming binary outcomes. However, the list is not so large for continuous outcomes though many real clinical trials deal with
continuous treatment responses. In the present paper, we attempt to explore the available procedures together with a comparison of their performances. Some real life adaptive trial is also reviewed.</p>
      </abstract>
      <kwd-group>
        <kwd>response-adaptive allocation</kwd>
        <kwd>continuous responses</kwd>
        <kwd>covariate</kwd>
        <kwd>delayed response</kwd>
        <kwd>urn model.</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
<sec id="sec1-0000000000000000">
<title>Introduction-test</title>
<p>A medical experiment on human beings should be aimed to provide best possible care for the individual patients. Traditional balanced treatment allocation, in the two-treatment set up, suggests allocating incoming patients to a treatment by tossing a fair coin. But such a 50:50 allocation has often been challenged due to its possible unethical consequences. Connor and et al.<sup><xref ref-type="bibr" rid="bibr1-0000000000000000">1</xref></sup> and Zelen and Wei<sup><xref ref-type="bibr" rid="bibr2-0000000000000000">2</xref></sup> discussed the results of the trial of the drug AZT in reducing the risk of maternal-to-infant HIV transmission. A balanced allocation rule treated 238 pregnant women by AZT, while the rest (i.e. 238) received the placebo. It was observed that 60 newborns in the placebo group were HIV positive whereas only 20 HIV positives were found in the AZT group. This is an appreciable difference and suggests that adaptive allocation to the better treatment would have reduced the total number of HIV-positive babies. To illustrate some properties of adaptive designs, Yao and Wei<sup><xref ref-type="bibr" rid="bibr3-0000000000000000">3</xref></sup> assumed that the responses were instantaneous, although they were not so. The estimated probabilities of survival after observing all the responses from AZT and placebo are respectively 0.9160 and 0.7479 when the study endpoint is time-to-diagnosis of HIV in the newborn. Using these as the true values Yao and Wei<sup><xref ref-type="bibr" rid="bibr3-0000000000000000">3</xref></sup> observed that the randomized play-the-winner rule<sup><xref ref-type="bibr" rid="bibr4-0000000000000000">4</xref></sup>, a popular response-adaptive design would have resulted in an allocation of 300:176 in favour of AZT, and lives of 11 newborns could have been saved! Hence it is logical to design any trial in such a way that a modification becomes possible along the way using the observed responses.</p>
<p>An allocation procedure randomizing entering patients based on the accrued data so far is referred to as <italic>adaptive</italic>. According to FDA draft guidance, 2010, adaptive randomization is a form of treatment allocation in which the probability of patient assignment to any particular treatment is adjusted based on repeated comparative analysis of the allocation and response data accrued so far. Naturally the randomization schedule across the study can change frequently or continuously over the duration of the study. However, such randomization is adopted when the outcomes are immediate and are observed faster than the study enrolment.</p>
<p>For a comprehensive classification of different allocation procedures, we consider a clinical trial with sequentially entered patients, each of whom is to be assigned to either of the <inline-formula id="ilml1-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math1-0000000000000000"><mml:mi>t</mml:mi></mml:math></inline-formula> competing treatments. Let <inline-formula id="ilml2-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math2-0000000000000000"><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> be the treatment indicator (<inline-formula id="ilml3-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math3-0000000000000000"><mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> or 0 according as treatment <inline-formula id="ilml4-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math4-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula> is applied or not) and <inline-formula id="ilml5-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math5-0000000000000000"><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> be the response that would have been observed if treatment <inline-formula id="ilml6-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math6-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula> was assigned to the <inline-formula id="ilml7-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math7-0000000000000000"><mml:mi>j</mml:mi></mml:math></inline-formula>th subject, <inline-formula id="ilml8-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math8-0000000000000000"><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:math></inline-formula>; <inline-formula id="ilml9-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math9-0000000000000000"><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x22EF;</mml:mi></mml:mrow></mml:math></inline-formula>, and in addition, let <inline-formula id="ilml10-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math10-0000000000000000"><mml:msub><mml:mtext mathvariant="bold">&#x1D419;</mml:mtext><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> denote the corresponding vector of covariate information. Let <inline-formula id="ilml11-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math11-0000000000000000"><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x1D4AF;</mml:mi></mml:mstyle><mml:mi>n</mml:mi></mml:msub></mml:math></inline-formula>, <inline-formula id="ilml12-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math12-0000000000000000"><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x1D4B3;</mml:mi></mml:mstyle><mml:mi>n</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula id="ilml13-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math13-0000000000000000"><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x1D4B5;</mml:mi></mml:mstyle><mml:mi>n</mml:mi></mml:msub></mml:math></inline-formula> denote, respectively, the information (i.e. <inline-formula id="ilml14-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math14-0000000000000000"><mml:mi>&#x3C3;</mml:mi></mml:math></inline-formula>-algebra) contained in the first <inline-formula id="ilml15-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math15-0000000000000000"><mml:mi>n</mml:mi></mml:math></inline-formula> treatment assignments, responses and covariates. In addition we denote the available <italic>data</italic> by <inline-formula id="ilml16-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math16-0000000000000000"><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x2131;</mml:mi></mml:mstyle><mml:mi>n</mml:mi></mml:msub></mml:math></inline-formula> ,which is the totality of all response, allocation and covariate information up to the <inline-formula id="ilml17-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math17-0000000000000000"><mml:mi>n</mml:mi></mml:math></inline-formula>th subject plus the covariate information of the <inline-formula id="ilml18-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math18-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>th subject. Then any allocation scheme can be defined by the conditional expectation <disp-formula id="disp-formula1-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math1-0000000000000000"><mml:mrow><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>&#x2223;</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x2131;</mml:mi></mml:mstyle><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>,</mml:mo><mml:mspace width="0.222em"/><mml:mspace width="0.222em"/><mml:mi>n</mml:mi><mml:mo>&#x2265;</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mspace width="0.222em"/><mml:mspace width="0.222em"/><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xlink:href="10.1177_0000000000000000-eq1.tif" specific-use="disp-formula1-0000000000000000"/></alternatives></disp-formula> and depending on the use of available <italic>data</italic>, we can classify a data-dependent allocation (or, a randomization procedure) in the following way.</p>
<list list-type="unorder" id="list1-0000000000000000">
<list-item><p><italic>Allocation-adaptive randomization:</italic></p>
<p><inline-formula id="ilml19-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math19-0000000000000000"><mml:mrow><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>&#x2223;</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x2131;</mml:mi></mml:mstyle><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>&#x2223;</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x1D4AF;</mml:mi></mml:mstyle><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>;</mml:mo></mml:mrow></mml:math></inline-formula></p></list-item>
<list-item><p><italic>Response-adaptive randomization:</italic></p>
<p><inline-formula id="ilml20-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math20-0000000000000000"><mml:mrow><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>&#x2223;</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x2131;</mml:mi></mml:mstyle><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>&#x2223;</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x1D4AF;</mml:mi></mml:mstyle><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x1D4B3;</mml:mi></mml:mstyle><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>;</mml:mo></mml:mrow></mml:math></inline-formula></p></list-item>
<list-item><p><italic>Covariate-adaptive randomization:</italic></p>
<p><inline-formula id="ilml21-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math21-0000000000000000"><mml:mrow><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>&#x2223;</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x2131;</mml:mi></mml:mstyle><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>&#x2223;</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x1D4AF;</mml:mi></mml:mstyle><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x1D4B5;</mml:mi></mml:mstyle><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>;</mml:mo></mml:mrow></mml:math></inline-formula> and</p></list-item>
<list-item><p><italic>Covariate-adjusted response-adaptive randomization:</italic></p>
<p><inline-formula id="ilml22-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math22-0000000000000000"><mml:mrow><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>&#x2223;</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x2131;</mml:mi></mml:mstyle><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>&#x2223;</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x1D4AF;</mml:mi></mml:mstyle><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x1D4B3;</mml:mi></mml:mstyle><mml:mrow><mml:mi>n</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x1D4B5;</mml:mi></mml:mstyle><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mi>.</mml:mi></mml:mrow></mml:math></inline-formula></p></list-item>
</list>
<p>Thus, in a response-adaptive design, whenever the observed data reveals the superiority of a treatment arm, the allocation probability get skewed in favour of the better performing treatment and hence the allocation tend to favour this arm ensuring more allocation to this treatment<sup><xref ref-type="bibr" rid="bibr5-0000000000000000">5</xref></sup>, on an average. The preliminary ideas in this direction can be found in Thompson<sup><xref ref-type="bibr" rid="bibr6-0000000000000000">6</xref></sup> and Robbins<sup><xref ref-type="bibr" rid="bibr7-0000000000000000">7</xref></sup>, followed by Anscombe<sup><xref ref-type="bibr" rid="bibr8-0000000000000000">8</xref></sup> and Colton<sup><xref ref-type="bibr" rid="bibr9-0000000000000000">9</xref></sup>. A brief history including the recent developments can be found in Rosenberger and Lachin<sup><xref ref-type="bibr" rid="bibr10-0000000000000000">10</xref></sup>, Rosenberger<sup><xref ref-type="bibr" rid="bibr11-0000000000000000">11</xref></sup> and the booklength discussions of Rosenberger and Lachin<sup><xref ref-type="bibr" rid="bibr12-0000000000000000">12</xref></sup>, Chow and Chang<sup><xref ref-type="bibr" rid="bibr13-0000000000000000">13</xref></sup> and Hu and Rosenberger<sup><xref ref-type="bibr" rid="bibr14-0000000000000000">14</xref></sup>.</p>
<p>Most of the available works in response-adaptive designs are for binary treatment outcomes. Examples include the play-the-winner rule<sup><xref ref-type="bibr" rid="bibr15-0000000000000000">15</xref></sup>, the randomized play-the-winner rule<sup><xref ref-type="bibr" rid="bibr4-0000000000000000">4</xref></sup>, the success driven design<sup><xref ref-type="bibr" rid="bibr16-0000000000000000">16</xref></sup>, the drop-the-loser design<sup><xref ref-type="bibr" rid="bibr17-0000000000000000">17</xref></sup>, and the generalised drop-the-loser design<sup><xref ref-type="bibr" rid="bibr18-0000000000000000">18</xref></sup>, among others. A detailed discussion of the designs up to 2001 is available in Biswas<sup><xref ref-type="bibr" rid="bibr19-0000000000000000">19</xref></sup>. But, in many clinical trials, the primary outcome may be of continuous type. Wilson, Lacourci<inline-formula id="ilml23-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math23-0000000000000000"><mml:mover><mml:mi>e</mml:mi><mml:mo accent="true">`</mml:mo></mml:mover></mml:math></inline-formula>re and Barnes<sup><xref ref-type="bibr" rid="bibr20-0000000000000000">20</xref></sup> considered office-recorded diastolic blood pressure reduction much earlier as the primary outcome to evaluate the antihypertensive efficacy of losartan and amlodipine. The Hamilton depression rating scale (HDRS) is used as the primary outcome to measure depression in many trials<sup><xref ref-type="bibr" rid="bibr21-0000000000000000">21</xref>,<xref ref-type="bibr" rid="bibr22-0000000000000000">22</xref></sup>. Dworkin and his colleagues<sup><xref ref-type="bibr" rid="bibr23-0000000000000000">23</xref></sup> reported a clinical trial to investigate the efficacy of pregabalin in the treatment of postherpetic neuralgia where the primary efficacy measure was an 11-point numerical pain rating score. This can also be treated as a continuous variable<sup><xref ref-type="bibr" rid="bibr24-0000000000000000">24</xref>,<xref ref-type="bibr" rid="bibr25-0000000000000000">25</xref>,<xref ref-type="bibr" rid="bibr26-0000000000000000">26</xref></sup>. Time to event is of interest in some situations. For example, Fu et al.<sup><xref ref-type="bibr" rid="bibr27-0000000000000000">27</xref></sup> considered a clinical trial to evaluate the efficacy of topical recombinant bovine basic fibroblast growth factor for second degree burns, considered wound healing time as the primary outcome.</p>
<p>The present paper is a review of the available works on response-adaptive procedures with continuous responses. We start with the available adaptive procedures which are developed in an ad-hoc manner, in section 2. In section 3, we discuss the general formulation of an optimal target proportion together with the implementation in practice. The usefulness of incorporating covariate information for allocation of subjects is discussed in section 4. In section 5, we address a new consideration, namely efficiency, in response-adaptive randomization. Response-adaptive allocation schemes adjusted for delayed responses are discussed in section 6. In section 7 a comparative performance study of different allocation schemes are done by simulations. The comparion is also carried out with reference to a real clinical trials. Finally, we end up with a discussion of related and upcoming issues in section 8.</p>
</sec>
<sec id="sec2-0000000000000000">
<title>General Allocation Designs</title>
<sec id="sec3-0000000000000000">
<title>Nonparametric allocation procedures</title>
<p>Response-adaptive designs for binary responses are mostly based on urns with balls of different colours, representing different treatments. A patient is assigned to a treatment by drawing a ball at random from the urn. Based on patients&#x2019; responses (success/failure), balls are added or removed according to some random mechanism. Successes generally increase the balls representing the successful treatment whereas failures alternate the addition process. In this way, the urn composition becomes skewed in favour of the better performing treatment. However many clinical trials are long term survival trials producing continuous outcomes. But in most of the available works, there has been suggestions as to how to make a continuous response dichotomous by introducing some clinically relevant threshold<sup><xref ref-type="bibr" rid="bibr22-0000000000000000">22</xref>,<xref ref-type="bibr" rid="bibr28-0000000000000000">28</xref></sup>. For trials with continuous outcomes, Rosenberger<sup><xref ref-type="bibr" rid="bibr29-0000000000000000">29</xref></sup> was perhaps the first to develop a reasonable allocation design for general class of responses. He introduced the idea of <italic>treatment effect mapping</italic>, where the assignment probabilities are suitable functions of the current estimate of treatment effectiveness. The intuitive appeal of such a mapping is that the patients are allocated according to the currently available magnitudes of the treatment effect ensuring a larger number of assignments to the better treatment. To be specific, consider a two treatment clinical trial with treatments 1 and 2. Let <inline-formula id="ilml24-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math24-0000000000000000"><mml:msub><mml:mover><mml:mi>&#x394;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> be current estimate of <inline-formula id="ilml25-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math25-0000000000000000"><mml:mi>&#x394;</mml:mi></mml:math></inline-formula>, a suitable measure of treatment effectiveness, after <inline-formula id="ilml26-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math26-0000000000000000"><mml:mi>j</mml:mi></mml:math></inline-formula> responses. If a larger response is preferred, then a larger value of <inline-formula id="ilml27-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math27-0000000000000000"><mml:msub><mml:mover><mml:mi>&#x394;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> reflects the possible superiority of treatment 1 at that stage of the trial. Then the suggested rule assigns the <inline-formula id="ilml28-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math28-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>st subject to treatment 1 with probability <inline-formula id="ilml29-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math29-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mover><mml:mi>&#x394;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> for some continuous function <inline-formula id="ilml30-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math30-0000000000000000"><mml:mi>g</mml:mi></mml:math></inline-formula> on <inline-formula id="ilml31-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math31-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false" form="postfix">]</mml:mo></mml:mrow></mml:math></inline-formula> such that <inline-formula id="ilml32-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math32-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilml33-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math33-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>&gt;</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mspace width="0.222em"/><mml:mstyle mathvariant="normal"><mml:mi>i</mml:mi><mml:mi>f</mml:mi></mml:mstyle><mml:mi>x</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math></inline-formula> and, <inline-formula id="ilml34-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math34-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>&lt;</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mspace width="0.222em"/><mml:mstyle mathvariant="normal"><mml:mi>i</mml:mi><mml:mi>f</mml:mi></mml:mstyle><mml:mi>x</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn><mml:mi>.</mml:mi></mml:mrow></mml:math></inline-formula> Such a choice of <inline-formula id="ilml35-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math35-0000000000000000"><mml:mi>g</mml:mi></mml:math></inline-formula> allows to allocate more patients to treatment performing better. As an example, Rosenberger<sup><xref ref-type="bibr" rid="bibr29-0000000000000000">29</xref></sup> used <inline-formula id="ilml36-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math36-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:math></inline-formula> with the normalised linear rank test statistic as the measure of treatment difference. Yao and Wei<sup><xref ref-type="bibr" rid="bibr3-0000000000000000">3</xref></sup> used the same formulation with <disp-formula id="disp-formula2-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math2-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true" form="prefix">{</mml:mo><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mo>+</mml:mo><mml:mi>x</mml:mi><mml:mi>r</mml:mi></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mi>i</mml:mi><mml:mi>f</mml:mi></mml:mstyle><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:mi>x</mml:mi><mml:mi>r</mml:mi><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:mo>&#x2264;</mml:mo><mml:mn>.4</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mn>0.1</mml:mn></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mi>i</mml:mi><mml:mi>f</mml:mi></mml:mstyle><mml:mi>x</mml:mi><mml:mi>r</mml:mi><mml:mo>&lt;</mml:mo><mml:mo>&#x2212;</mml:mo><mml:mn>.4</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mn>0.9</mml:mn></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mi>i</mml:mi><mml:mi>f</mml:mi></mml:mstyle><mml:mi>x</mml:mi><mml:mi>r</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>.4</mml:mn><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math><graphic xlink:href="10.1177_0000000000000000-eq2.tif" specific-use="disp-formula2-0000000000000000"/></alternatives></disp-formula> where <inline-formula id="ilml37-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math37-0000000000000000"><mml:mi>r</mml:mi></mml:math></inline-formula> is a constant reflecting the experimenter&#x2019;s intention to adapt the trial. Standardized Gehan-Wilcoxon test statistic is used to measure the difference in treatment effectiveness. Rosenberger and Seshaiyer<sup><xref ref-type="bibr" rid="bibr30-0000000000000000">30</xref></sup> used the same technique in the context of a clinical trial with survival outcomes. Centered and scaled log rank statistic is used as a measure of treatment difference with <inline-formula id="ilml38-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math38-0000000000000000"><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>x</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:math></inline-formula> as the choice of <inline-formula id="ilml39-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math39-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>. However, the procedure was not studied in details.</p>
</sec>
<sec id="sec4-0000000000000000">
<title>Continuous drop-the-losers</title>
<p>Urn model is a popular tool to skew the allocation towards the better treatment arm. Most of the popularly used urn designs (e.g. the randomized play-the-winner rule) are actually birth processes and hence are highly variable, often leading to a loss in power of a relevant test of treatment equivalence. With a view to reduce variability of allocation proportion for any particular treatment or equivalently to enhance statistical power, Ivanova<sup><xref ref-type="bibr" rid="bibr17-0000000000000000">17</xref></sup> developed an urn based allocation design, called drop-the-loser. The allocation is actually a death process and consequently is less variable. A lower variability of the observed allocation proportion in small samples ensures a faster rate of achieving the limiting allocation proportion. Drop-the-loser, in fact, minimises the limiting variability of the observed allocation proportion<sup><xref ref-type="bibr" rid="bibr69-0000000000000000">69</xref></sup>. However the rule was initially developed with binary responses and subsequently modified<sup><xref ref-type="bibr" rid="bibr31-0000000000000000">31</xref></sup> for continuous responses. The urn initially contains balls of <inline-formula id="ilml40-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math40-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> types, balls of types <inline-formula id="ilml41-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math41-0000000000000000"><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:math></inline-formula> represent <inline-formula id="ilml42-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math42-0000000000000000"><mml:mi>t</mml:mi></mml:math></inline-formula> treatments and balls of type 0 are immigration balls. Whenever a subject arrives, a ball is removed from the urn and the subject is given treatment <inline-formula id="ilml43-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math43-0000000000000000"><mml:mi>j</mml:mi></mml:math></inline-formula> if it is a ball of <inline-formula id="ilml44-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math44-0000000000000000"><mml:mi>j</mml:mi></mml:math></inline-formula>th type, <inline-formula id="ilml45-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math45-0000000000000000"><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:math></inline-formula>, and his/her response is observed. For an immigration ball, no subject is treated, the ball is replaced and <inline-formula id="ilml46-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math46-0000000000000000"><mml:mi>t</mml:mi></mml:math></inline-formula> additional balls, one of each treatment type, is added to the urn. The procedure is repeated until a ball representing a treatment is obtained. If the response of the subject exceeds a clinically significant threshold (which does not vary throughout the trial) then the removed ball is replaced otherwise it is withdrawn from the urn. This is known as <italic>continuous drop-the-loser rule</italic>, which is abbreviated as the CDL. A randomised version of the above rule, suggesting to replace the ball drawn with probability depending on the outcome observed, is also provided. The procedure is studied explicitly for two treatments and a lower rate of variability is observed than the available competitors. Simulations also reveal a significantly higher assignment to the better treatment with a lower variability even for unequal response variances. In a recent work, Biswas and Bhattacharya<sup><xref ref-type="bibr" rid="bibr32-0000000000000000">32</xref></sup> provided some modification of the existing CDL design and extends the CDL rule to provide two new designs which have more or less the same allocation to the better treatment as that of the CDL, but the variability is shown to be 20-30% less than that of CDL. The allocation procedure is similar with CDL, except that after each response only fractions of the withdrawn ball is added to the urn. Naturally the urn may contain <italic>fractional balls</italic> at a particular time but this will not affect the allocation procedure as the allocation is carried out using computer generated random numbers. The theoretical results are also supported through a detailed simulation study.</p>
</sec>
<sec id="sec5-0000000000000000">
<title>A Wilcoxon-Mann-Whitney-type adaptive design</title>
<p>The Wilcoxon-Mann-Whitney-type adaptive design<sup><xref ref-type="bibr" rid="bibr33-0000000000000000">33</xref></sup> (WAD) is actually an urn based <italic>allocation-cum-testing</italic> procedure for two treatment continuous response trials, where after each response the urn is updated according to the value of a Wilcoxon-Mann-Whitney-type statistic. The design is studied theoretically and some asymptotic results together with an exactly distribution free solution for generalized Behrens-Fisher problem is derived. Specifically if we characterise the response from treatment 1 (2) by a continuous univariate distribution function <inline-formula id="ilml47-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math47-0000000000000000"><mml:mi>F</mml:mi></mml:math></inline-formula> (<inline-formula id="ilml48-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math48-0000000000000000"><mml:mi>G</mml:mi></mml:math></inline-formula>) with <inline-formula id="ilml49-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math49-0000000000000000"><mml:mrow><mml:mi>G</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mi>F</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mi>&#x394;</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>, then the limiting allocation to the better treatment (treatment 2 in this case) is established as <inline-formula id="ilml50-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math50-0000000000000000"><mml:mrow><mml:mo>&#x222B;</mml:mo><mml:mi>F</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mi>&#x394;</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mi>d</mml:mi><mml:mi>F</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>.</p>
</sec>
<sec id="sec6-0000000000000000">
<title>Doubly adaptive biased coin designs</title>
<p>All the rules discussed so far were developed with a strategy to assign more subjects to the better treatment, but not designed with a target proportion of allocation. Doubly adaptive biased coin design (DBCD) is a family of response adaptive procedures targeting a pre-specified allocation proportion. It was originally proposed by Eisele<sup><xref ref-type="bibr" rid="bibr34-0000000000000000">34</xref></sup> and subsequently modified and extended by many authors<sup><xref ref-type="bibr" rid="bibr35-0000000000000000">35</xref>,<xref ref-type="bibr" rid="bibr36-0000000000000000">36</xref></sup>. The procedure involves a target allocation as a function of unknown parameters of the response model, and sequentially substitutes updated estimates of the unknown parameters based on available data. To be specific, if the target allocation proportion of subjects to treatment 1 be <inline-formula id="ilml51-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math51-0000000000000000"><mml:mi>&#x3C1;</mml:mi></mml:math></inline-formula>, then the allocation is carried out through a function <inline-formula id="ilml52-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math52-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>&#x3C1;</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> from <inline-formula id="ilml53-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math53-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:msup><mml:mo stretchy="false" form="postfix">]</mml:mo><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> to <inline-formula id="ilml54-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math54-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false" form="postfix">]</mml:mo></mml:mrow></mml:math></inline-formula> which bridges the observed allocation proportion to the target allocation satisfying the following regularity conditions: (i) <inline-formula id="ilml55-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math55-0000000000000000"><mml:mi>g</mml:mi></mml:math></inline-formula> is jointly continuous, (ii) <inline-formula id="ilml56-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math56-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:math></inline-formula>, (iii) <inline-formula id="ilml57-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math57-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>&#x3C1;</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> is strictly decreasing in <inline-formula id="ilml58-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math58-0000000000000000"><mml:mi>x</mml:mi></mml:math></inline-formula> and strictly increasing in <inline-formula id="ilml59-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math59-0000000000000000"><mml:mi>&#x3C1;</mml:mi></mml:math></inline-formula> on <inline-formula id="ilml60-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math60-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:msup><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula>, and (iv) <inline-formula id="ilml61-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math61-0000000000000000"><mml:mi>g</mml:mi></mml:math></inline-formula> has bounded derivatives in both arguments. Then the procedure allocates the <inline-formula id="ilml62-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math62-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>st patient to treatment 1 with probability <inline-formula id="ilml63-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math63-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mfrac><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>j</mml:mi></mml:mfrac><mml:mo>,</mml:mo><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">&#x2C6;</mml:mo></mml:mover><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>, where <inline-formula id="ilml64-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math64-0000000000000000"><mml:mfrac><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>j</mml:mi></mml:mfrac></mml:math></inline-formula> is the observed proportion to treatment 1, <inline-formula id="ilml65-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math65-0000000000000000"><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">&#x2C6;</mml:mo></mml:mover><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> is the estimated target proportion after the <inline-formula id="ilml66-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math66-0000000000000000"><mml:mi>j</mml:mi></mml:math></inline-formula>th patient. The intuitive idea behind these regularity conditions is to ensure that <inline-formula id="ilml67-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math67-0000000000000000"><mml:mrow><mml:mi>g</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mfrac><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>j</mml:mi></mml:mfrac><mml:mo>,</mml:mo><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">&#x2C6;</mml:mo></mml:mover><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>&gt;</mml:mo><mml:mspace width="0.222em"/><mml:mstyle mathvariant="normal"><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mstyle><mml:mspace width="0.222em"/><mml:mo>&lt;</mml:mo><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">&#x2C6;</mml:mo></mml:mover><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> according as <inline-formula id="ilml68-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math68-0000000000000000"><mml:mrow><mml:mfrac><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>j</mml:mi></mml:mfrac><mml:mo>&lt;</mml:mo><mml:mspace width="0.222em"/><mml:mstyle mathvariant="normal"><mml:mi>o</mml:mi><mml:mi>r</mml:mi></mml:mstyle><mml:mspace width="0.222em"/><mml:mo>&gt;</mml:mo><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">&#x2C6;</mml:mo></mml:mover><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and ultimately <inline-formula id="ilml69-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math69-0000000000000000"><mml:mfrac><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mi>j</mml:mi></mml:mfrac></mml:math></inline-formula> and <inline-formula id="ilml70-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math70-0000000000000000"><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">&#x2C6;</mml:mo></mml:mover><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> become very close to the target proportion <inline-formula id="ilml71-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math71-0000000000000000"><mml:mi>&#x3C1;</mml:mi></mml:math></inline-formula>. Naturally, the choice of <inline-formula id="ilml72-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math72-0000000000000000"><mml:mi>g</mml:mi></mml:math></inline-formula> is an important concern. Eisele and Woodroofe<sup><xref ref-type="bibr" rid="bibr35-0000000000000000">35</xref></sup> gave a set of conditions that the allocation function <inline-formula id="ilml73-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math73-0000000000000000"><mml:mi>g</mml:mi></mml:math></inline-formula> should satisfy to ensure the target allocation <inline-formula id="ilml74-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math74-0000000000000000"><mml:mi>&#x3C1;</mml:mi></mml:math></inline-formula> in the limit. But these conditions are very restrictive and are usually difficult to check. In fact, the choice of <inline-formula id="ilml75-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math75-0000000000000000"><mml:mi>g</mml:mi></mml:math></inline-formula>, suggested by Eisele and Woodroofe<sup><xref ref-type="bibr" rid="bibr35-0000000000000000">35</xref></sup> violates their own regularity conditions<sup><xref ref-type="bibr" rid="bibr37-0000000000000000">37</xref></sup>. In a follow up work, Hu and Zhang<sup><xref ref-type="bibr" rid="bibr36-0000000000000000">36</xref></sup> suggested the following family of allocation functions: <disp-formula id="disp-formula3-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math3-0000000000000000"><mml:mrow><mml:msup><mml:mi>g</mml:mi><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>&#x3B3;</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>&#x3C1;</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true" form="prefix">{</mml:mo><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mn>1</mml:mn></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mspace width="0.222em"/><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.222em"/></mml:mstyle><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mfrac><mml:mrow><mml:mi>&#x3C1;</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mfrac><mml:mi>&#x3C1;</mml:mi><mml:mi>x</mml:mi></mml:mfrac><mml:msup><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mi>&#x3B3;</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:mi>&#x3C1;</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mfrac><mml:mi>&#x3C1;</mml:mi><mml:mi>x</mml:mi></mml:mfrac><mml:msup><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mi>&#x3B3;</mml:mi></mml:msup><mml:mo>+</mml:mo><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x2212;</mml:mo><mml:mi>&#x3C1;</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x2212;</mml:mo><mml:mi>&#x3C1;</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x2212;</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:mfrac><mml:msup><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mi>&#x3B3;</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mspace width="0.222em"/><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.222em"/></mml:mstyle><mml:mn>0</mml:mn><mml:mo>&lt;</mml:mo><mml:mi>x</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mn>0</mml:mn></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mspace width="0.222em"/><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.222em"/></mml:mstyle><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math><graphic xlink:href="10.1177_0000000000000000-eq3.tif" specific-use="disp-formula3-0000000000000000"/></alternatives></disp-formula> together with a set of alternative conditions to ensure the desired target in the limit. The parameter <inline-formula id="ilml76-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math76-0000000000000000"><mml:mrow><mml:mi>&#x3B3;</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mo>&#x2265;</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> controls the randomness of the procedure. Different choices of <inline-formula id="ilml77-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math77-0000000000000000"><mml:mi>&#x3B3;</mml:mi></mml:math></inline-formula> produces different allocation procedures, a large value of <inline-formula id="ilml78-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math78-0000000000000000"><mml:mi>&#x3B3;</mml:mi></mml:math></inline-formula> provides an allocation design with smaller variance but decreases the degree of randomness. Therefore, an appropriate choice of <inline-formula id="ilml79-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math79-0000000000000000"><mml:mi>&#x3B3;</mml:mi></mml:math></inline-formula> should maintain a balance between the degree of randomization and the variability. For <inline-formula id="ilml80-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math80-0000000000000000"><mml:mrow><mml:mi>&#x3B3;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>, we have <inline-formula id="ilml81-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math81-0000000000000000"><mml:mrow><mml:msup><mml:mi>g</mml:mi><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>&#x3B3;</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>&#x3C1;</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mi>&#x3C1;</mml:mi></mml:mrow></mml:math></inline-formula>, which leads to <italic>Sequential Maximum Likelihood Procedure</italic><sup><xref ref-type="bibr" rid="bibr38-0000000000000000">38</xref></sup> (SMLE), where at each stage <inline-formula id="ilml82-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math82-0000000000000000"><mml:mi>&#x3C1;</mml:mi></mml:math></inline-formula> is estimated, preferably by the method of maximum likelihood, and the next incoming subject is assigned to treatment 1 with this probability. However to start any allocation procedure using sequential estimation, some data must be available to compute the allocation probabilities at the initial stage. This necessitates the experimenter to allocate some patients initially to either treatment, perhaps by equal randomization or by some permuted block design. Properties of the SMLE procedure targeting two treatment Neyman allocation are explored by Melfi, Page and Zeraldes<sup><xref ref-type="bibr" rid="bibr37-0000000000000000">37</xref></sup>. Hu and Zhang<sup><xref ref-type="bibr" rid="bibr36-0000000000000000">36</xref></sup> showed that, under some favourable conditions, with probability one <inline-formula id="ilml83-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math83-0000000000000000"><mml:mrow><mml:msub><mml:mi>lim</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo accent="false">&#x2192;</mml:mo><mml:mi>&#x221E;</mml:mi></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>n</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow><mml:mi>n</mml:mi></mml:mfrac><mml:mo>=</mml:mo><mml:mi>&#x3C1;</mml:mi></mml:mrow></mml:math></inline-formula>, where <inline-formula id="ilml84-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math84-0000000000000000"><mml:mi>&#x3C1;</mml:mi></mml:math></inline-formula> depends on the unknown parameter of the response distributions. They<sup><xref ref-type="bibr" rid="bibr36-0000000000000000">36</xref></sup> also provided a multi-treatment generalization of the above supported by some related asymptotic results.
Along the same line, as a compromise between <italic>ethics</italic> and <italic>optimality</italic>, Bandyopadhyay and Bhattacharya<sup><xref ref-type="bibr" rid="bibr39-0000000000000000">39</xref></sup>, provided a SMLE procedure, which targets the allocation probability <disp-formula id="disp-formula4-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math4-0000000000000000"><mml:mrow><mml:mo stretchy="true" form="prefix">{</mml:mo><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mi>max</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mfrac><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mi>J</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mi>i</mml:mi><mml:mi>f</mml:mi></mml:mstyle><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x2265;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mi>min</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mfrac><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mi>J</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mi>i</mml:mi><mml:mi>f</mml:mi></mml:mstyle><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math><graphic xlink:href="10.1177_0000000000000000-eq4.tif" specific-use="disp-formula4-0000000000000000"/></alternatives></disp-formula> where <inline-formula id="ilml85-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math85-0000000000000000"><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> and <inline-formula id="ilml86-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math86-0000000000000000"><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula> are respectively the mean and variance of the response variable from treatment <inline-formula id="ilml87-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math87-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula>, <inline-formula id="ilml88-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math88-0000000000000000"><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilml89-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math89-0000000000000000"><mml:mi>J</mml:mi></mml:math></inline-formula> is some symmetric non-decreasing function and <inline-formula id="ilml90-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math90-0000000000000000"><mml:mrow><mml:mi>T</mml:mi><mml:mo>&#x2208;</mml:mo><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x221E;</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> is a tuning factor (may be parameter dependent). They have also provided some related asymptotic results and justified the gain in statistical and ethical precision, both by means of a simulation study.</p>
</sec>
<sec id="sec7-0000000000000000">
<title>Kernel Based Allocation Designs</title>
<p>Most of the available allocation designs require the existence of the first two moments of the response variables, but that is not always ensured in clinical response data because the responses may follow a heavy-tailed distribution. The work by Imrey and Kingman<sup><xref ref-type="bibr" rid="bibr40-0000000000000000">40</xref></sup> explore the possibility of such heavy-tailed response by means of a QQ plot. They provide a plot of one-year Electric Caries Meter measurements from teeth of the 47 Lithuanian children, and observe that the QQ plot is more vertical at both ends than for the usual normal response data resembling the QQ plot for Cauchy responses. Consequently, the parametric response-adaptive designs will fail in such a situation. Naturally, kernel based compound allocation function with specific weights to ethics and optimality is appropriate in this context<sup><xref ref-type="bibr" rid="bibr25-0000000000000000">25</xref></sup>. Specifically <disp-formula id="disp-formula5-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math5-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3C0;</mml:mi><mml:mi>&#x3B1;</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>&#x3B1;</mml:mi><mml:mspace width="0.222em"/><mml:mi>P</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mn>21</mml:mn></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>+</mml:mo><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x2212;</mml:mo><mml:mi>&#x3B1;</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:mo>&gt;</mml:mo><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mn>21</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mn>22</mml:mn></mml:msub><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math><graphic xlink:href="10.1177_0000000000000000-eq5.tif" specific-use="disp-formula5-0000000000000000"/></alternatives></disp-formula> was considered as the allocation function for treatment 1. Clearly, <inline-formula id="ilml91-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math91-0000000000000000"><mml:mrow><mml:mi>&#x3B1;</mml:mi><mml:mo>&#x2208;</mml:mo><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> is a trade-off between ethics and optimality, and it should carefully be chosen before any application. They<sup><xref ref-type="bibr" rid="bibr25-0000000000000000">25</xref></sup> also provided a <italic>self weighted</italic> version, where <inline-formula id="ilml92-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math92-0000000000000000"><mml:mi>&#x3B1;</mml:mi></mml:math></inline-formula> is determined sequentially depending on the current proportional treatment imbalance together with the results of a detailed simulation for responses without any finite moments. Along the same line of thinking, the authors provided a variation of the above allocation<sup><xref ref-type="bibr" rid="bibr26-0000000000000000">26</xref></sup> in a very recent work by replacing <inline-formula id="ilml93-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math93-0000000000000000"><mml:mrow><mml:mi>P</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:mo>&gt;</mml:mo><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mn>21</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mn>22</mml:mn></mml:msub><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> by <inline-formula id="ilml94-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math94-0000000000000000"><mml:mrow><mml:mi>P</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msubsup><mml:mi>X</mml:mi><mml:mn>11</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&gt;</mml:mo><mml:msubsup><mml:mi>X</mml:mi><mml:mn>21</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mi>.</mml:mi></mml:mrow></mml:math></inline-formula></p>
</sec>
</sec>
<sec id="sec8-0000000000000000">
<title>Optimal response-adaptive designs</title>
<sec id="sec9-0000000000000000">
<title>Optimality in clinical trials</title>
<p>Most of the designs discussed so far were developed with the intuitive goal to assign more subjects to the better treatment. But skewing the allocation towards the better performing treatment, in general, leads to a loss in statistical power and this particular phenomena limits the practitioners to recommend response adaptive randomization in real trials. To balance between ethical consideration and preservation of statistical power, Jennison and Turnbull<sup><xref ref-type="bibr" rid="bibr41-0000000000000000">41</xref></sup> suggested to develop the target allocation using a constrained optimization problem. For the optimization problem, the objective function is taken to be a measure of ethics and the constraint is a function of power or vice versa. The solution of the optimization problem gives the optimal proportion, randomized to a treatment. Hardwick and Stout<sup><xref ref-type="bibr" rid="bibr42-0000000000000000">42</xref></sup> reviewed several criteria that one may wish to optimize which includes expected number of failures, the total expected sample size, expected number of allocations to the inferior treatment and total expected cost. However, the approach of Hardwick and Stout<sup><xref ref-type="bibr" rid="bibr42-0000000000000000">42</xref></sup> was to compute optimal designs using computationally intensive methods for various sequential allocation problems.</p>
</sec>
<sec id="sec10-0000000000000000">
<title>Allocations with two treatments</title>
<sec id="sec11-0000000000000000">
<title>Standard formulation</title>
<p>For the development of an optimal allocation design, what we primarily need is a clinically relevant criterion, minimisation of which is required to satisfy a subject. If <inline-formula id="ilml95-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math95-0000000000000000"><mml:msub><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> subjects are assigned to treatment <inline-formula id="ilml96-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math96-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula> in a non-randomised manner then for any relevant ethical metric function <inline-formula id="ilml97-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math97-0000000000000000"><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>, the objective function can be expressed as <inline-formula id="ilml98-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math98-0000000000000000"><mml:mrow><mml:mi>G</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>. The choice of <inline-formula id="ilml99-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math99-0000000000000000"><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> is objective specific. That is, if the objective is to minimize total sample size then <inline-formula id="ilml100-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math100-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> whereas for the minimization of total expected response <inline-formula id="ilml101-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math101-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> with <inline-formula id="ilml102-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math102-0000000000000000"><mml:msub><mml:mi>X</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> denoting the potential response of a subject assigned treatment <inline-formula id="ilml103-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math103-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula>. But minimisation of <inline-formula id="ilml104-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math104-0000000000000000"><mml:mi>G</mml:mi></mml:math></inline-formula> alone results in degenerate rules and this necessitates the consideration of another criterion. In fact, in any clinical trial, apart from satisfying the ethical imperative, keeping a high level of power for a relevant test is also required. In this context, Biswas, Bhattacharya and Zhang<sup><xref ref-type="bibr" rid="bibr43-0000000000000000">43</xref></sup> provided a general technique to obtain optimal target allocations for continuous responses assuming that <inline-formula id="ilml105-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math105-0000000000000000"><mml:msub><mml:mi>X</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> has a continuous distribution with mean <inline-formula id="ilml106-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math106-0000000000000000"><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> and finite variance <inline-formula id="ilml107-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math107-0000000000000000"><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula> , <inline-formula id="ilml108-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math108-0000000000000000"><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>. If under a hypothetical set up, <inline-formula id="ilml109-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math109-0000000000000000"><mml:msub><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> subjects are assigned to treatment <inline-formula id="ilml110-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math110-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula> in a non-randomised manner, the variance of the estimator of the usual treatment difference, <inline-formula id="ilml111-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math111-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>, can be obtained as <inline-formula id="ilml112-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math112-0000000000000000"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mfrac></mml:mrow></mml:math></inline-formula>. Naturally, a lower value of <inline-formula id="ilml113-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math113-0000000000000000"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mfrac></mml:mrow></mml:math></inline-formula> ensures a higher power for testing <inline-formula id="ilml114-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math114-0000000000000000"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> using Wald test. Thus the derivation of an optimal target allocation is equivalent to the following constrained optimisation problem: <disp-formula id="disp-formula6-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math6-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mi>M</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq6.tif" specific-use="disp-formula6-0000000000000000"/></alternatives></disp-formula> subject to the restriction <disp-formula id="disp-formula7-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math7-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mfrac><mml:mo>&#x2264;</mml:mo><mml:mi>&#x3BA;</mml:mi><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq7.tif" specific-use="disp-formula7-0000000000000000"/></alternatives></disp-formula> where <inline-formula id="ilml115-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math115-0000000000000000"><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> is a strictly positive function of <inline-formula id="ilml116-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math116-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilml117-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math117-0000000000000000"><mml:mi>&#x3BA;</mml:mi></mml:math></inline-formula> is a constant. A straightforward algebra gives the optimal proportion to treatment 1 as <disp-formula id="disp-formula8-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math8-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:msup><mml:mi>&#x3C1;</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mfrac><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msqrt><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:msqrt></mml:mrow><mml:mrow><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msqrt><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:msqrt><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msqrt><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:msqrt></mml:mrow></mml:mfrac><mml:mi>.</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq8.tif" specific-use="disp-formula8-0000000000000000"/></alternatives></disp-formula> However, <inline-formula id="ilml118-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math118-0000000000000000"><mml:msup><mml:mi>&#x3C1;</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:math></inline-formula> depends on the unknown parameters and a natural way to utilize the optimal proportion for the randomization of subjects is to replace the unknown parameters with their available estimates. We then require a rule(e.g. DBCD) which will use these sequentially estimated proportions to skew the allocation. In the simplest case, an optimal rule assigns the <inline-formula id="ilml119-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math119-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>st patient to treatment 1 with probability <inline-formula id="ilml120-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math120-0000000000000000"><mml:mover><mml:msubsup><mml:mi>&#x3C1;</mml:mi><mml:mi>j</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo accent="true">^</mml:mo></mml:mover></mml:math></inline-formula>, where <inline-formula id="ilml121-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math121-0000000000000000"><mml:mover><mml:msubsup><mml:mi>&#x3C1;</mml:mi><mml:mi>j</mml:mi><mml:mo>*</mml:mo></mml:msubsup><mml:mo accent="true">^</mml:mo></mml:mover></mml:math></inline-formula> is preferably the maximum likelihood estimate of <inline-formula id="ilml122-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math122-0000000000000000"><mml:msup><mml:mi>&#x3C1;</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:math></inline-formula> after <inline-formula id="ilml123-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math123-0000000000000000"><mml:mi>j</mml:mi></mml:math></inline-formula> patients have responded. Note that the above optimisation problem is quite similar with the formulation of Jennison and Turnbull<sup><xref ref-type="bibr" rid="bibr41-0000000000000000">41</xref></sup>, where <inline-formula id="ilml124-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math124-0000000000000000"><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> were functions of treatment difference <inline-formula id="ilml125-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math125-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>. But Biswas and his collaborators<sup><xref ref-type="bibr" rid="bibr43-0000000000000000">43</xref></sup> assumed <inline-formula id="ilml126-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math126-0000000000000000"><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> as a function of the parameters of the response distribution for the <inline-formula id="ilml127-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math127-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula>th treatment for easy interpretation and possible extension with more than two treatments. Different choices of <inline-formula id="ilml128-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math128-0000000000000000"><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>s, reflecting different goal of the trial, provide different allocation rules. However, only a few optimal adaptive designs are available for continuous responses and we list them below.</p>
<p>If <inline-formula id="ilml129-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math129-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> for each <inline-formula id="ilml130-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math130-0000000000000000"><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, then as indicated earlier, the optimisation problem is equivalent to minimize the total sample size for fixed variance of the estimated treatment difference. The optimal solution is the well known Neyman allocation <inline-formula id="ilml131-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math131-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3C1;</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> for two treatments. Melfi and his colleagues<sup><xref ref-type="bibr" rid="bibr37-0000000000000000">37</xref></sup> studied the randomized design that targets this proportion and established that under certain regularity assumptions, the optimal allocation ratio <inline-formula id="ilml132-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math132-0000000000000000"><mml:msub><mml:mi>&#x3C1;</mml:mi><mml:mi>N</mml:mi></mml:msub></mml:math></inline-formula>, to treatment 1 is attained in the limit.</p>
<p>Suppose the aim is to minimise the overall failure proportion in a trial where higher responses are treated as favourable. Unlike binary response trials, the failure is not rigidly defined when the response is continuous. Since a higher response is desirable, the proportion of responses less than a clinically significant threshold <inline-formula id="ilml133-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math133-0000000000000000"><mml:mi>c</mml:mi></mml:math></inline-formula> could be used to measure the proportion of failure. This suggests to take <inline-formula id="ilml134-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math134-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>&lt;</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>, where <inline-formula id="ilml135-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math135-0000000000000000"><mml:msub><mml:mi>X</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> represents the response variable corresponding to the <inline-formula id="ilml136-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math136-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula>th treatment and the resulting allocation is nothing but the optimal allocation of Biswas and Mandal<sup><xref ref-type="bibr" rid="bibr44-0000000000000000">44</xref></sup>. Considering exponential and normal responses they derived the explicit expressions of the optimal proportion but did not investigate the theoretical properties in detail. The success of the above procedure depends heavily on the choice of <inline-formula id="ilml137-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math137-0000000000000000"><mml:mi>c</mml:mi></mml:math></inline-formula>, a larger choice of <inline-formula id="ilml138-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math138-0000000000000000"><mml:mi>c</mml:mi></mml:math></inline-formula> makes the failure proportion higher whereas a smaller choice reduces the proportion significantly. However, the average expected response may be a sensible choice for <inline-formula id="ilml139-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math139-0000000000000000"><mml:mi>c</mml:mi></mml:math></inline-formula>.</p>
<p>Next suppose a lower response is desirable and consequently one may wish to minimise the total expected response of the patients. Zhang and Rosenberger<sup><xref ref-type="bibr" rid="bibr24-0000000000000000">24</xref></sup> used this formulation under normal responses and considered the optimisation problem with <inline-formula id="ilml140-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math140-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. Quite naturally the optimal proportion to treatment 1 is <disp-formula id="disp-formula9-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math9-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:msub><mml:mi>&#x3C1;</mml:mi><mml:mrow><mml:mi>Z</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msqrt><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:msqrt></mml:mrow><mml:mrow><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msqrt><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:msqrt><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msqrt><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:msqrt></mml:mrow></mml:mfrac><mml:mi>.</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq9.tif" specific-use="disp-formula9-0000000000000000"/></alternatives></disp-formula> However, it is important to note that, in real practice the allocation may be meaningless (impossible to implement). A simulation study with this allocation target revealed that whenever at any stage of the experiment, at least one of the estimated <inline-formula id="ilml141-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math141-0000000000000000"><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> becomes negative, the simulation process crashes down without generating any output<sup><xref ref-type="bibr" rid="bibr43-0000000000000000">43</xref></sup>. In fact in a recent work<sup><xref ref-type="bibr" rid="bibr32-0000000000000000">32</xref></sup>, it is established that <inline-formula id="ilml142-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math142-0000000000000000"><mml:msub><mml:mi>&#x3C1;</mml:mi><mml:mrow><mml:mi>Z</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> no longer remains the optimal solution when at least one of the <inline-formula id="ilml143-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math143-0000000000000000"><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>&#x2019;s are negative. The optimality is preserved only for positive valued response distributions (e.g. exponential or two parameter gamma). In this context a modification<sup><xref ref-type="bibr" rid="bibr43-0000000000000000">43</xref></sup> could be to replace <inline-formula id="ilml144-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math144-0000000000000000"><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> by <inline-formula id="ilml145-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math145-0000000000000000"><mml:mrow><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> with <inline-formula id="ilml146-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math146-0000000000000000"><mml:msub><mml:mi>X</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>. A variety of optimal target proportions together with the performance explaining detailed simulation study can be found in the work of Biswas and his collaborators<sup><xref ref-type="bibr" rid="bibr43-0000000000000000">43</xref></sup>.</p>
<p>The above discussion is based on a single clinically relevant criterion, but in real situations there may be additional clinical constraints to control simultaneously. Such a procedure can be found in Bandyopadhyay and Bhattacharya<sup><xref ref-type="bibr" rid="bibr45-0000000000000000">45</xref></sup> where, using a combined objective function, simultaneous minimisation of treatment failures and allocation to the inferior treatment is considered, subject to a fixed level of statistical precision. An investigation of the performance of the proposed procedure for a general class of responses can also be found. Along the same line, Biswas and Bhattacharya<sup><xref ref-type="bibr" rid="bibr46-0000000000000000">46</xref></sup> developed another optimal target with an aim to maximise the power of a test of treatment equivalence keeping both the treatment failures and the allocation to the inferior treatment at a low level.</p>
</sec>
<sec id="sec12-0000000000000000">
<title>Optimal design based formulation</title>
<p>Another class of optimal designs can be found in Antognini and Giovangoli<sup><xref ref-type="bibr" rid="bibr47-0000000000000000">47</xref></sup>, where optimum design theory<sup><xref ref-type="bibr" rid="bibr48-0000000000000000">48</xref></sup> is used to derive various optimal targets. Assuming that the treatment outcome (i.e. response) has a distribution belonging to a regular exponential family, they obtained the unconditional Fisher&#x2019;s information matrix <inline-formula id="ilml147-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math147-0000000000000000"><mml:mi>M</mml:mi></mml:math></inline-formula>. Then any design minimising <inline-formula id="ilml148-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math148-0000000000000000"><mml:mrow><mml:mi>&#x3D5;</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msup><mml:mi>M</mml:mi><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>, a convex function of the inverse of Fisher&#x2019;s information matrix, is <italic>optimal</italic>. Possible choices of <inline-formula id="ilml149-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math149-0000000000000000"><mml:mi>&#x3D5;</mml:mi></mml:math></inline-formula> could be the <inline-formula id="ilml150-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math150-0000000000000000"><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msup><mml:mi>M</mml:mi><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>, giving the A-optimal design, <inline-formula id="ilml151-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math151-0000000000000000"><mml:mrow><mml:mi>log</mml:mi><mml:mo stretchy="false" form="prefix">|</mml:mo><mml:msup><mml:mi>M</mml:mi><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false" form="prefix">|</mml:mo></mml:mrow></mml:math></inline-formula>, giving the D-optimal design or the maximum eigenvalue of <inline-formula id="ilml152-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math152-0000000000000000"><mml:msup><mml:mi>M</mml:mi><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, giving the E-optimal design. For normally distributed responses, the A-optimal design leads to the target <inline-formula id="ilml153-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math153-0000000000000000"><mml:mfrac><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula>, the well known Neyman allocation of survey sampling; the E-optimal design leads to the target <inline-formula id="ilml154-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math154-0000000000000000"><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mrow><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:math></inline-formula>; whereas D-optimal design reduces to the completely random allocation. In a real trial the procedures can be applied by using sequentially updated estimates of the parameters at each stage. They<sup><xref ref-type="bibr" rid="bibr47-0000000000000000">47</xref></sup> established that under certain restrictions, the randomisation procedure converges to the optimal allocation proportion. However the procedure is not attractive ethically as the target completely ignores the treatment effectiveness and hence the better treatment can be under-represented if the variability is lower.</p>
</sec>
<sec id="sec13-0000000000000000">
<title>Allocations for survival outcomes</title>
<p>Many clinical trials have time-to-event outcomes, with an an inherent delay in survival time responses, with possible censoring. Zhang and Rosenberger<sup><xref ref-type="bibr" rid="bibr49-0000000000000000">49</xref></sup> presented an optimal allocation procedure incorporating the possible presence of censoring and delay. Assuming exponential responses subject to right censoring, they have derived the optimal proportion by minimising the total expected hazard. The optimal proportion can be obtained from the general optimisation problem taking <inline-formula id="ilml155-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math155-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilml156-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math156-0000000000000000"><mml:mrow><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:msubsup><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>&#x3F5;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mfrac></mml:mrow></mml:math></inline-formula>, where <inline-formula id="ilml157-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math157-0000000000000000"><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> is the expected response for the <inline-formula id="ilml158-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math158-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula>th treatment and <inline-formula id="ilml159-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math159-0000000000000000"><mml:msub><mml:mi>&#x3F5;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> is the fixed non-censoring proportion for the subjects with treatment <inline-formula id="ilml160-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math160-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula>, <inline-formula id="ilml161-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math161-0000000000000000"><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>. Consequently the optimal allocation proportion to treatment 1 takes the form <disp-formula id="disp-formula10-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math10-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:msqrt><mml:mrow><mml:msubsup><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn><mml:mn>3</mml:mn></mml:msubsup><mml:msub><mml:mi>&#x3F5;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:msqrt><mml:mrow><mml:msqrt><mml:mrow><mml:msubsup><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn><mml:mn>3</mml:mn></mml:msubsup><mml:msub><mml:mi>&#x3F5;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:msqrt><mml:mo>+</mml:mo><mml:msqrt><mml:mrow><mml:msubsup><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn><mml:mn>3</mml:mn></mml:msubsup><mml:msub><mml:mi>&#x3F5;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac><mml:mi>.</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq10.tif" specific-use="disp-formula10-0000000000000000"/></alternatives></disp-formula> They have also considered minimisation of the total number of subjects in the trial, which corresponds to the choice <inline-formula id="ilml162-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math162-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilml163-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math163-0000000000000000"><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, and hence obtained the proportion <disp-formula id="disp-formula11-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math11-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msqrt><mml:msub><mml:mi>&#x3F5;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:msqrt></mml:mrow><mml:mrow><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msqrt><mml:msub><mml:mi>&#x3F5;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:msqrt><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msqrt><mml:msub><mml:mi>&#x3F5;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:msqrt></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq11.tif" specific-use="disp-formula11-0000000000000000"/></alternatives></disp-formula> an analogue to the well known Neyman allocation for survival outcomes. The corresponding optimal proportions for Weibull distribution are also obtained. The exact properties of the procedures are investigated through a simulation study using uniform censoring for both the treatments. In addition, some relevant asymptotic results are also established.</p>
</sec>
</sec>
<sec id="sec14-0000000000000000">
<title>More than two treatments</title>
<p>Formulation of an optimal target proportion for <inline-formula id="ilml164-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math164-0000000000000000"><mml:mrow><mml:mi>t</mml:mi><mml:mspace width="0.222em"/><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mo>&gt;</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> treatments is not just a straightforward extension of what we have discussed for two treatments. It is rather difficult as the variance function is not defined uniquely, and hence different formulations of the problem are possible. One such formulation with binary responses can be found in Tymofyeyev, Rosenberger and Hu<sup><xref ref-type="bibr" rid="bibr50-0000000000000000">50</xref></sup>, where the non-centrality parameter of the contrast test of homogeneity is substituted for the variance function. Specifically they provided a multi-treatment analogue of Neyman allocation for an arbitrary number of treatments with binary outcomes. With continuous responses, the non-centrality parameter for testing <inline-formula id="ilml165-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math165-0000000000000000"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> can be expressed as <disp-formula id="disp-formula12-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math12-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mi>&#x3D5;</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:msup><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>j</mml:mi><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>&#x2212;</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>t</mml:mi></mml:munderover><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>j</mml:mi><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mo stretchy="true" form="prefix">{</mml:mo><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>j</mml:mi><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="true" form="postfix">}</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq12.tif" specific-use="disp-formula12-0000000000000000"/></alternatives></disp-formula> where treatment <inline-formula id="ilml166-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math166-0000000000000000"><mml:mi>t</mml:mi></mml:math></inline-formula> is considered as control. Then continuous analogue could be the following optimisation problem: <disp-formula id="disp-formula13-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math13-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mstyle mathvariant="normal"><mml:mspace width="0.222em"/><mml:mi>M</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.222em"/></mml:mstyle><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>t</mml:mi></mml:munderover><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq13.tif" specific-use="disp-formula13-0000000000000000"/></alternatives></disp-formula> subject to the restrictions <disp-formula id="disp-formula14-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math14-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mi>&#x3D5;</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>&#x2265;</mml:mo><mml:mi>&#x3BA;</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq14.tif" specific-use="disp-formula14-0000000000000000"/></alternatives></disp-formula> and <disp-formula id="disp-formula15-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math15-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mrow><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>t</mml:mi></mml:munderover><mml:msub><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#x2265;</mml:mo><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.222em"/><mml:mspace width="0.222em"/><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mo>*</mml:mo><mml:mo>*</mml:mo><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mrow><mml:mi>B</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq15.tif" specific-use="disp-formula15-0000000000000000"/></alternatives></disp-formula> where <inline-formula id="ilml167-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math167-0000000000000000"><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> is a measure of clinical effectiveness for treatment <inline-formula id="ilml168-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math168-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula>, <inline-formula id="ilml169-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math169-0000000000000000"><mml:mrow><mml:mi>&#x3BA;</mml:mi><mml:mspace width="0.222em"/><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> is a constant and <inline-formula id="ilml170-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math170-0000000000000000"><mml:mrow><mml:mi>B</mml:mi><mml:mo>&#x2208;</mml:mo><mml:mo stretchy="false" form="prefix">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msup><mml:mi>t</mml:mi><mml:mrow><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false" form="postfix">]</mml:mo></mml:mrow></mml:math></inline-formula> ensures an explicit control over the target proportions. But no explicit form solution is worked out for the above optimisation problem. However, with exponentially distributed responses, Zhu and Hu<sup><xref ref-type="bibr" rid="bibr51-0000000000000000">51</xref></sup> derived the target proportion with <inline-formula id="ilml171-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math171-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilml172-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math172-0000000000000000"><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula>, <inline-formula id="ilml173-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math173-0000000000000000"><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:math></inline-formula>, and assessed the implemented procedure in terms of both the assignment fraction to the best treatment and power of a test of treatment equivalence. An alternative formulation can be found in Biswas, Mandal and Bhattacharya<sup><xref ref-type="bibr" rid="bibr52-0000000000000000">52</xref></sup>, where the target proportion is obtained as a solution to the following optimisation problem <disp-formula id="disp-formula16-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math16-0000000000000000"><mml:mrow><mml:mstyle mathvariant="normal"><mml:mi>M</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>i</mml:mi><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.222em"/></mml:mstyle><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>t</mml:mi></mml:munderover><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math><graphic xlink:href="10.1177_0000000000000000-eq16.tif" specific-use="disp-formula16-0000000000000000"/></alternatives></disp-formula> subject to the restrictions <disp-formula id="disp-formula17-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math17-0000000000000000"><mml:mrow><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>t</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mfrac><mml:mo>&#x2264;</mml:mo><mml:msub><mml:mi>&#x3BA;</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mspace width="0.222em"/><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xlink:href="10.1177_0000000000000000-eq17.tif" specific-use="disp-formula17-0000000000000000"/></alternatives></disp-formula> where and <inline-formula id="ilml174-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math174-0000000000000000"><mml:msub><mml:mi>&#x3BA;</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math></inline-formula> are constants and <inline-formula id="ilml175-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math175-0000000000000000"><mml:mi>&#x3A8;</mml:mi></mml:math></inline-formula>&#x2019;s are strictly positive. With equal <inline-formula id="ilml176-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math176-0000000000000000"><mml:mi>&#x3BA;</mml:mi></mml:math></inline-formula>&#x2019;s they obtained the optimal solution <disp-formula id="disp-formula18-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math18-0000000000000000"><mml:mrow><mml:msub><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mfrac><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mrow><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>k</mml:mi></mml:munderover><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mrow><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true" form="prefix">{</mml:mo><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mrow><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msqrt><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>t</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mfrac></mml:msqrt><mml:msqrt><mml:mrow><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mspace width="0.222em"/><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.222em"/></mml:mstyle><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mfrac><mml:mrow><mml:msqrt><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>t</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mfrac></mml:msqrt><mml:msqrt><mml:mrow><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:msqrt></mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:mi>&#x22EF;</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msqrt><mml:mfrac><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>t</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mfrac></mml:msqrt><mml:msqrt><mml:mrow><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mspace width="0.222em"/><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.222em"/></mml:mstyle><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>t</mml:mi><mml:mi>.</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math><graphic xlink:href="10.1177_0000000000000000-eq18.tif" specific-use="disp-formula18-0000000000000000"/></alternatives></disp-formula> But for unequal <inline-formula id="ilml177-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math177-0000000000000000"><mml:mi>&#x3BA;</mml:mi></mml:math></inline-formula>&#x2019;s the solution can be obtained through some numerical procedures. Biswas et al.<sup><xref ref-type="bibr" rid="bibr52-0000000000000000">52</xref></sup> explored such an allocation for continuous responses and assessed the procedure both theoretically and numerically. For survival trials, Sverdlov, Tymofyeyev and Wong<sup><xref ref-type="bibr" rid="bibr53-0000000000000000">53</xref></sup> considered the formulation exactly as in (refref) and obtained the target proportions assuming exponential responses under random censoring schemes. Analytical details are given for <inline-formula id="ilml178-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math178-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, but only numerical details are provided when <inline-formula id="ilml179-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math179-0000000000000000"><mml:msub><mml:mi>&#x3A8;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> represents the hazard for the <inline-formula id="ilml180-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math180-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula>th treatment. Since the optimal proportions depend on unknown parameters, they implemented the allocation using sequentially updated maximum likelihood estimates within the framework of a DBCD procedure<sup><xref ref-type="bibr" rid="bibr36-0000000000000000">36</xref></sup>. Various design and inference related aspects of the allocation are investigated even under the presence of delay.
At this point, we note that the optimal target proportion is unknown and an estimate of the optimal proportion based on the available data is used as the randomization probability for the next entering patient. As a result, instead of fixed allocation probability for each subject under the trial, we get varying allocation probabilities. Naturally the so called <italic>optimality</italic> is not preserved at the intermediate stages. But the <italic>optimality</italic> is retained in the long run in the sense that the observed allocation proportions/probabilities at different stages converge stochastically to the optimal target proportion under widely satisfied regularity conditions.</p>
</sec>
</sec>
<sec id="sec15-0000000000000000">
<title>Incorporating covariate information</title>
<sec id="sec16-0000000000000000">
<title>Covariate dependent designs</title>
<p>In a modern clinical trials, in addition to the primary outcome, information on several covariates is collected. Since human beings are complex organisms, their responses to therapy are expected to be influenced by the respective covariate information. For example, the effect of a hypertensive drug depends on age, initial blood pressure and cholesterol level of the patient. Again the effectiveness of a therapy to cancer may depend on the smoking habit, initial size of the tumour of the patient, among other covariates. Thus it is reasonable to allow the allocation of the current patient to depend not only on responses of the previous patients but also on the covariates. But only a few works utilising covariate information are available in literature.</p>
<p>Begg and Iglewicz<sup><xref ref-type="bibr" rid="bibr54-0000000000000000">54</xref></sup> used the optimum design theory where a deterministic treatment allocation rule is derived in the presence of covariate. Atkinson<sup><xref ref-type="bibr" rid="bibr55-0000000000000000">55</xref></sup> also used the optimum design theory to provide an allocation procedure for an arbitrary number of treatments under the presence of covariate information. Some recent developments in this direction can be found in Atkinson<sup><xref ref-type="bibr" rid="bibr56-0000000000000000">56</xref>,<xref ref-type="bibr" rid="bibr57-0000000000000000">57</xref></sup>, Atkinson and Biswas<sup><xref ref-type="bibr" rid="bibr58-0000000000000000">58</xref></sup> and Wong and Zhu<sup><xref ref-type="bibr" rid="bibr59-0000000000000000">59</xref></sup>. All these procedures except that of Atkinson and Biswas<sup><xref ref-type="bibr" rid="bibr58-0000000000000000">58</xref></sup>, are actually <italic>covariate-adaptive</italic>, not <italic>response-adaptive</italic>, as the responses are completely ignored while assigning the next patient. The purpose of such an allocation design is to provide a guard against potential biases as well as balancing the covariates across treatments. Thus these rules may assign fewer patients to the better treatment arm and hence can not be appreciated from a clinician&#x2019;s point of view.</p>
<p>The link function based simple design of Bandyopadhyay and Biswas<sup><xref ref-type="bibr" rid="bibr60-0000000000000000">60</xref></sup> is perhaps the first attempt to allocate patients in an ethical way using the covariate information. Also this is perhaps the first attempt to use the totality of the continuous responses without using nonparametric scores. The design, even without covariates, is still very popular and used in constructing more complicated designs by others. Considering a homoscedastic linear model with common error variances and under the normality of responses they have suggested the allocation probability <inline-formula id="ilml181-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math181-0000000000000000"><mml:mrow><mml:mi>J</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mfrac><mml:msub><mml:mover><mml:mi>&#x394;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula> for the <inline-formula id="ilml182-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math182-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>st patient to treatment 1, where <inline-formula id="ilml183-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math183-0000000000000000"><mml:msub><mml:mover><mml:mi>&#x394;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> is the observed value of the treatment difference <inline-formula id="ilml184-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math184-0000000000000000"><mml:mrow><mml:mi>&#x394;</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> based on the allocation, response and covariate information of previous <inline-formula id="ilml185-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math185-0000000000000000"><mml:mi>i</mml:mi></mml:math></inline-formula> subjects and <inline-formula id="ilml186-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math186-0000000000000000"><mml:mi>T</mml:mi></mml:math></inline-formula> is a positive tuning parameter which may be a function of the error variance (<inline-formula id="ilml187-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math187-0000000000000000"><mml:mi>T</mml:mi></mml:math></inline-formula> may sequentially be estimated in that case). Here <inline-formula id="ilml188-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math188-0000000000000000"><mml:mi>J</mml:mi></mml:math></inline-formula> is the cumulative distribution function (cdf) of a random variable which is symmetric about 0. The most obvious choice of <inline-formula id="ilml189-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math189-0000000000000000"><mml:mi>J</mml:mi></mml:math></inline-formula> is <inline-formula id="ilml190-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math190-0000000000000000"><mml:mi>&#x3A6;</mml:mi></mml:math></inline-formula>, the cdf of a standard normal distribution. The procedure also works well without the presence of covariates, and for non-normal distributions of responses. Quite naturally a larger number of assignments to the better treatment is expected. In fact if a sufficiently large number of patients are treated, then the limiting allocation proportion to treatment 1 is derived as <inline-formula id="ilml191-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math191-0000000000000000"><mml:mrow><mml:mi>&#x3A6;</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mfrac><mml:mi>&#x394;</mml:mi><mml:mi>T</mml:mi></mml:mfrac><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>. A generalized version of the above allocation for multivariate responses is also available<sup><xref ref-type="bibr" rid="bibr61-0000000000000000">61</xref></sup>.</p>
<p>Biswas, Huang and Huang<sup><xref ref-type="bibr" rid="bibr62-0000000000000000">62</xref></sup> proposed an urn based allocation design under the assumption of a normal linear model with homoscedasticity. The procedure is similar to the formulation of continuous drop-the-loser<sup><xref ref-type="bibr" rid="bibr31-0000000000000000">31</xref></sup> except that, in addition, we have covariate information for each entering subject. Then, depending on the allocation, response and the covariate information up to the current patient (i.e. the <inline-formula id="ilml192-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math192-0000000000000000"><mml:mi>i</mml:mi></mml:math></inline-formula>th patient), we return the selected ball with probability <inline-formula id="ilml193-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math193-0000000000000000"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, a reasonable function of the data accumulated prior to the entrance of the <inline-formula id="ilml194-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math194-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>st patient. In the binary version of the drop-the-loser<inline-formula id="ilml195-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math195-0000000000000000"><mml:msup><mml:mi/><mml:mn>17</mml:mn></mml:msup></mml:math></inline-formula>, the ball was replaced for a success and withdrawn whenever a failure occurs. But for a continuous response model, some sensible threshold is set to get the ball replacement probability<sup><xref ref-type="bibr" rid="bibr62-0000000000000000">62</xref></sup>. The authors also investigated the relevant performance measures through an extensive simulation study.</p>
<p>However the covariate information of any subject is generally known prior to his/her entrance and hence it seems sensible to use the current patient&#x2019;s covariate to determine the allocation. Such an allocation strategy is consistent with the primary aim of a clinical trial and is referred to as <italic>covariate adjusted response adaptive</italic> (or CARA) randomisation procedure<sup><xref ref-type="bibr" rid="bibr14-0000000000000000">14</xref></sup>. An extensive study of CARA procedures together with the relevant asymptotic properties and possible extension for several treatments are also available in recent literature<sup><xref ref-type="bibr" rid="bibr63-0000000000000000">63</xref>,<xref ref-type="bibr" rid="bibr64-0000000000000000">64</xref></sup>. Examining the rules already discussed, we note that the optimal rule of Biswas and Mandal<sup><xref ref-type="bibr" rid="bibr44-0000000000000000">44</xref></sup> is the only allocation design that fits into a CARA randomisation procedure. Also the link function based design can be easily put in that way. In fact, the multi-treatment multivariate generalization of the link function based design, given by Biswas and Coad<sup><xref ref-type="bibr" rid="bibr61-0000000000000000">61</xref></sup> is a CARA design. These<sup><xref ref-type="bibr" rid="bibr44-0000000000000000">44</xref>,<xref ref-type="bibr" rid="bibr61-0000000000000000">61</xref></sup> were proposed even before the formal introduction of CARA design<sup><xref ref-type="bibr" rid="bibr14-0000000000000000">14</xref></sup>.</p>
</sec>
<sec id="sec17-0000000000000000">
<title>Optimal covariate dependent designs</title>
<p>The covariate dependent allocation designs of Atkinson<sup><xref ref-type="bibr" rid="bibr55-0000000000000000">55</xref>,<xref ref-type="bibr" rid="bibr56-0000000000000000">56</xref>,<xref ref-type="bibr" rid="bibr57-0000000000000000">57</xref></sup>, Atkinson and Biswas<sup><xref ref-type="bibr" rid="bibr58-0000000000000000">58</xref></sup> and Wong and Zhu<sup><xref ref-type="bibr" rid="bibr59-0000000000000000">59</xref></sup> are all <italic>optimal</italic> in the sense that they minimise the variability of the estimated treatment difference incorporating covariates. However, among the available covariate dependent allocation designs for continuous responses, Biswas and Mandal<sup><xref ref-type="bibr" rid="bibr44-0000000000000000">44</xref></sup> provided a way to incorporate covariate information with an aim to minimise treatment failures subject to some inferential gain. With the notations already introduced, we further assume that the response of the <inline-formula id="ilml196-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math196-0000000000000000"><mml:mi>i</mml:mi></mml:math></inline-formula>th subject treated by treatment <inline-formula id="ilml197-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math197-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula> is normally distributed with mean <inline-formula id="ilml198-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math198-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mstyle mathvariant="bold"><mml:mi>&#x1D6C3;</mml:mi></mml:mstyle><mml:mi>T</mml:mi></mml:msup><mml:msub><mml:mstyle mathvariant="bold"><mml:mi>&#x1D419;</mml:mi></mml:mstyle><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and variance <inline-formula id="ilml199-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math199-0000000000000000"><mml:msup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula>, where vectors of covariate information are independently and identically normal random variables with mean vector <inline-formula id="ilml200-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math200-0000000000000000"><mml:mstyle mathvariant="bold"><mml:mi>&#x1D6CF;</mml:mi></mml:mstyle></mml:math></inline-formula> and covariance matrix <inline-formula id="ilml201-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math201-0000000000000000"><mml:mi>&#x3A3;</mml:mi></mml:math></inline-formula>. Then the expected number of responses less than a threshold <inline-formula id="ilml202-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math202-0000000000000000"><mml:mi>c</mml:mi></mml:math></inline-formula> when all the patients have a fixed covariate vector <inline-formula id="ilml203-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math203-0000000000000000"><mml:msub><mml:mstyle mathvariant="bold"><mml:mi>&#x1D419;</mml:mi></mml:mstyle><mml:mn>0</mml:mn></mml:msub></mml:math></inline-formula>, can be expressed as <disp-formula id="disp-formula19-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math19-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mi>&#x3A6;</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mfrac><mml:mrow><mml:mi>c</mml:mi><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msup><mml:mstyle mathvariant="bold"><mml:mi>&#x1D6C3;</mml:mi></mml:mstyle><mml:mi>T</mml:mi></mml:msup><mml:msub><mml:mstyle mathvariant="bold"><mml:mi>&#x1D419;</mml:mi></mml:mstyle><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mi>&#x3C3;</mml:mi></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mi>&#x3A6;</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mfrac><mml:mrow><mml:mi>c</mml:mi><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msup><mml:mstyle mathvariant="bold"><mml:mi>&#x1D6C3;</mml:mi></mml:mstyle><mml:mi>T</mml:mi></mml:msup><mml:msub><mml:mstyle mathvariant="bold"><mml:mi>&#x1D419;</mml:mi></mml:mstyle><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mi>&#x3C3;</mml:mi></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq19.tif" specific-use="disp-formula19-0000000000000000"/></alternatives></disp-formula> where <inline-formula id="ilml204-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math204-0000000000000000"><mml:msub><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> is the allocation number to treatment <inline-formula id="ilml205-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math205-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula>, <inline-formula id="ilml206-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math206-0000000000000000"><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>. Then fixing the unconditional variance of the estimated treatment difference at some preassigned value the optimal proportion to treatment 1 is <disp-formula id="disp-formula20-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math20-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mfrac><mml:mrow><mml:mi>&#x3A6;</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mfrac><mml:mrow><mml:mi>c</mml:mi><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msup><mml:mstyle mathvariant="bold"><mml:mi>&#x1D6C3;</mml:mi></mml:mstyle><mml:mi>T</mml:mi></mml:msup><mml:msub><mml:mstyle mathvariant="bold"><mml:mi>&#x1D419;</mml:mi></mml:mstyle><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mi>&#x3C3;</mml:mi></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>&#x3A6;</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mfrac><mml:mrow><mml:mi>c</mml:mi><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:msup><mml:mstyle mathvariant="bold"><mml:mi>&#x1D6C3;</mml:mi></mml:mstyle><mml:mi>T</mml:mi></mml:msup><mml:msub><mml:mstyle mathvariant="bold"><mml:mi>&#x1D419;</mml:mi></mml:mstyle><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mi>&#x3C3;</mml:mi></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mi>&#x3A6;</mml:mi><mml:mrow><mml:mo stretchy="true" form="prefix">(</mml:mo><mml:mfrac><mml:mrow><mml:mi>c</mml:mi><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&#x2212;</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>b</mml:mi><mml:mi>f</mml:mi><mml:msup><mml:mi>&#x3B2;</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:msub><mml:mstyle mathvariant="bold"><mml:mi>&#x1D419;</mml:mi></mml:mstyle><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mi>&#x3C3;</mml:mi></mml:mfrac><mml:mo stretchy="true" form="postfix">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mfrac><mml:mi>.</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq20.tif" specific-use="disp-formula20-0000000000000000"/></alternatives></disp-formula> In real situations, parameters are no longer known and are to be replaced by the corresponding estimates, based on the available data and <inline-formula id="ilml207-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math207-0000000000000000"><mml:msub><mml:mstyle mathvariant="bold"><mml:mi>&#x1D419;</mml:mi></mml:mstyle><mml:mn>0</mml:mn></mml:msub></mml:math></inline-formula> by the covariate vector of the next entering subject. But in practice, the effect of covariate is not uniform and hence the assumption that all patients have a fixed covariate vector is often a concern for the clinicians. In a recent work, Antognini and Zagoraiou<sup><xref ref-type="bibr" rid="bibr65-0000000000000000">65</xref></sup> addressed the same problem and proposed a compound criterion combining ethical and inferential aspects. Minimizing the compound criterion, they derived a locally optimal target and implemented through a DBCD. But the target does not involve any covariate and hence the corresponding procedure is not covariate adjusted. However, all these allocations do not account for the treatment-covariate interaction<sup><xref ref-type="bibr" rid="bibr66-0000000000000000">66</xref></sup> and hence the covariates affect the responses in the same way for every patient. This is undesirable as the subjects with worst prognosis should get the better treatment. For example consider a hypothetical clinical trial on reducing systolic blood pressure of patients with age as the only covariate. In general, the response to a treatment of blood pressure reduction varies with age and it is realistic to assume that the experimental treatment (i.e. treatment 1) is more efficient than the Control (i.e. treatment 2) for all age groups but the effectiveness for both the treatments is the highest for the young patients, moderate for the middle aged and the lowest for the old aged. Naturally, the need for the best treatment is most (least) for old (young) aged patients and the presence of <italic>treatment-covariate interaction</italic> in the model ensures benefit according to the patient&#x2019;s covariate. In a recent work, Bandyopadhyay and Bhattacharya<sup><xref ref-type="bibr" rid="bibr67-0000000000000000">67</xref></sup> thoroughly investigated the effect of <italic>treatment-covariate interaction</italic> on the ethical properties under a response adaptive framework.</p>
</sec>
<sec id="sec18-0000000000000000">
<title>Bayesian Viewpoint</title>
<p>Although most of the works in the literature has been developed in frequentist&#x2019;s viewpoint, the basic principle of <italic>response-adaptive designs</italic> is basically Bayesian where the accrued data up to any stage plays the role of a <italic>prior</italic> at that stage and decides the allocation for the next entering subject. But, in the <italic>response-adaptive designs</italic>, the allocation probabilities are set ad-hoc based on the observed data up to that stage, not explicitly following any Bayesian posterior calculation. However, Biswas and Angers<sup><xref ref-type="bibr" rid="bibr68-0000000000000000">68</xref></sup> considered a continuous response two treatment set up in the presence of covariates. The set-up is similar to that of Bandyopadhyay and Biswas<sup><xref ref-type="bibr" rid="bibr60-0000000000000000">60</xref></sup>, but the procedure is actually a CARA randomization procedure, again before the formal introduction of CARA design<sup><xref ref-type="bibr" rid="bibr14-0000000000000000">14</xref></sup>. The allocation of any entering subject is carried out by computing the predictive density of a suitable link function that bridges the past history to the allocation. The usefulness of the proposed design is explored both theoretically and numerically (i.e. through a simulation study).</p>
</sec>
</sec>
<sec id="sec19-0000000000000000">
<title>Efficiency: A new consideration in Adaptive Allocation</title>
<p>Response-adaptive procedures discussed so far attempt to assign more subjects to the better performing treatment by using the available allocation and response history for the randomization of every incoming subject. But unbalanced allocation often leads to a loss in power for comparing treatment effectiveness. In recent years a great deal of attention has been paid to find a theoretical basis to evaluate adaptive procedures in terms of power or efficiency. The issue of efficiency in response adaptive randomization was addressed by many authors and under widely satisfied regularity conditions it is established that the efficiency is a decreasing function of the variability of the observed allocation proportion for any given target allocation<sup><xref ref-type="bibr" rid="bibr69-0000000000000000">69</xref>,<xref ref-type="bibr" rid="bibr70-0000000000000000">70</xref></sup>. In addition a lower bound to the asymptotic variance of observed allocation proportion for targeting a specific allocation proportion is obtained<sup><xref ref-type="bibr" rid="bibr70-0000000000000000">70</xref></sup>. A target allocation proportion attaining such a bound is referred to as the <italic>asymptotically best</italic><sup><xref ref-type="bibr" rid="bibr70-0000000000000000">70</xref></sup> and the corresponding response adaptive design is termed <italic>first-order efficient</italic><sup><xref ref-type="bibr" rid="bibr71-0000000000000000">71</xref></sup> or <italic>efficient</italic><sup><xref ref-type="bibr" rid="bibr71-0000000000000000">71</xref></sup> for that specified target. However, most of the available response-adaptive allocation designs are not <italic>efficient</italic> except for the binary response drop-the-loser procedures<sup><xref ref-type="bibr" rid="bibr17-0000000000000000">17</xref>,<xref ref-type="bibr" rid="bibr18-0000000000000000">18</xref></sup>. Although an efficient design for the general types of responses can be obtained from a DBCD<sup><xref ref-type="bibr" rid="bibr36-0000000000000000">36</xref></sup> but unfortunately, it results in a deterministic procedure, contradicting the basic requirement of &#x2018;randomization&#x2019; in a clinical trial. As a reasonable alternative to DBCD allocation, Hu and his collaborators<sup><xref ref-type="bibr" rid="bibr71-0000000000000000">71</xref></sup> developed a new family of efficient randomized adaptive designs (ERADE) to target any desired allocation. Specifically with <inline-formula id="ilml208-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math208-0000000000000000"><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#x2264;</mml:mo><mml:mi>&#x3B1;</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> as a tuning constant for degree of randomness, they suggest the following assignment scheme for the <inline-formula id="ilml209-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math209-0000000000000000"><mml:mrow><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mrow></mml:math></inline-formula>th patient <disp-formula id="disp-formula21-0000000000000000"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="block" id="math21-0000000000000000"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mi>E</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>&#x2223;</mml:mo><mml:msub><mml:mstyle mathvariant="script"><mml:mi>&#x2131;</mml:mi></mml:mstyle><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true" form="prefix">{</mml:mo><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mi>&#x3B1;</mml:mi><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mi>i</mml:mi><mml:mi>f</mml:mi></mml:mstyle><mml:mspace width="0.222em"/><mml:mfrac><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>i</mml:mi></mml:mfrac><mml:mo>&gt;</mml:mo><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mi>i</mml:mi><mml:mi>f</mml:mi></mml:mstyle><mml:mspace width="0.222em"/><mml:mfrac><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>i</mml:mi></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mn>1</mml:mn><mml:mo>&#x2212;</mml:mo><mml:mi>&#x3B1;</mml:mi><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo></mml:mtd><mml:mtd columnalign="left"><mml:mstyle mathvariant="normal"><mml:mi>i</mml:mi><mml:mi>f</mml:mi></mml:mstyle><mml:mspace width="0.222em"/><mml:mfrac><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>i</mml:mi></mml:mfrac><mml:mo>&lt;</mml:mo><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="10.1177_0000000000000000-eq21.tif" specific-use="disp-formula21-0000000000000000"/></alternatives></disp-formula> where <inline-formula id="ilml210-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math210-0000000000000000"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>i</mml:mi></mml:msubsup><mml:msub><mml:mi>&#x3B4;</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilml211-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math211-0000000000000000"><mml:msub><mml:mover><mml:mi>&#x3C1;</mml:mi><mml:mo accent="true">^</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula> denote respectively the observed number of allocations to treatment <inline-formula id="ilml212-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math212-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula> and an estimate of the target proportion <inline-formula id="ilml213-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math213-0000000000000000"><mml:mi>&#x3C1;</mml:mi></mml:math></inline-formula> based on the available response and allocation data up to and including the <inline-formula id="ilml214-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math214-0000000000000000"><mml:mi>i</mml:mi></mml:math></inline-formula>th subject. For <inline-formula id="ilml215-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math215-0000000000000000"><mml:mrow><mml:mi>&#x3B1;</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>, the procedure becomes deterministic whereas a more randomized procedure is ensured with higher values of <inline-formula id="ilml216-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math216-0000000000000000"><mml:mrow><mml:mi>&#x3B1;</mml:mi><mml:mi>.</mml:mi></mml:mrow></mml:math></inline-formula> It is interesting to note that the procedure reduces to Efron&#x2019;s famous <italic>biased coin design</italic><sup><xref ref-type="bibr" rid="bibr72-0000000000000000">72</xref></sup> when <inline-formula id="ilml217-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math217-0000000000000000"><mml:mrow><mml:mi>&#x3C1;</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mi>.</mml:mi></mml:mrow></mml:math></inline-formula> ERADE is established to be efficient for any target allocation as long as the response distribution belongs to the exponential family. Limiting results are also supported by relevant numerical computations for a number of target allocations taking into account both discrete and continuous treatment outcomes.</p>
</sec>
<sec id="sec20-0000000000000000">
<title>Delayed Responses</title>
<p>Most of the designs, discussed so far are developed with the assumption of instantaneous patient responses. But, in clinical trials, not only for survival outcomes, one need to adapt based on the available data so far. Early works<sup><xref ref-type="bibr" rid="bibr28-0000000000000000">28</xref>,<xref ref-type="bibr" rid="bibr30-0000000000000000">30</xref>,<xref ref-type="bibr" rid="bibr73-0000000000000000">73</xref>,<xref ref-type="bibr" rid="bibr74-0000000000000000">74</xref></sup> on response-adaptive procedures evaluated the effect of delay through a simulation study, but the theoretical results were explicitly obtained by Bai, Hu and Rosenberger<sup><xref ref-type="bibr" rid="bibr75-0000000000000000">75</xref></sup> and Biswas<sup><xref ref-type="bibr" rid="bibr76-0000000000000000">76</xref></sup>. For continuous responses Bandyopadhyay and Biswas<sup><xref ref-type="bibr" rid="bibr60-0000000000000000">60</xref></sup> briefly mentioned the possibility of delayed responses and suggested to carry out the adaptation procedure with available data. Biswas and Coad<sup><xref ref-type="bibr" rid="bibr61-0000000000000000">61</xref></sup> gave a full mathematical treatment to this problem assuming exponential rate of entrance of patients in the context of a general multi-treatment adaptive design. Assuming exponentially distributed delay, Zhang and Rosenberger<sup><xref ref-type="bibr" rid="bibr24-0000000000000000">24</xref></sup> also explored the effects of possible delay. Through a simulation study, they noted that moderate delay has marginal effect on the large sample behaviour of the randomisation procedure. Hu and his collaborators<sup><xref ref-type="bibr" rid="bibr77-0000000000000000">77</xref></sup> gave a full mathematical treatment to explore the effects of delayed responses. Assuming that the probability of a patient to respond before the arrival of <inline-formula id="ilml218-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math218-0000000000000000"><mml:mi>n</mml:mi></mml:math></inline-formula> additional patients is inversely proportional to <inline-formula id="ilml219-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math219-0000000000000000"><mml:msup><mml:mi>n</mml:mi><mml:mi>c</mml:mi></mml:msup></mml:math></inline-formula> for some <inline-formula id="ilml220-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math220-0000000000000000"><mml:mrow><mml:mi>c</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>, they showed that the asymptotic results of the DBCD procedures still hold. Assuming the patient entry intervals to be independent and identically distributed exponential, Zhang and Rosenberger<sup><xref ref-type="bibr" rid="bibr49-0000000000000000">49</xref></sup> established, as expected, that under very general conditions, the delayed response has no effect on the asymptotic properties of the randomization procedure.</p>
</sec>
<sec id="sec21-0000000000000000">
<title>A comparative study</title>
<sec id="sec22-0000000000000000">
<title>Simulation study</title>
<p>To compare the performances of various allocation rules, we conduct a simulation study with 10,000 repetitions. For simplicity, we ignore the presence of any covariate information and assume that the responses from treatment <inline-formula id="ilml221-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math221-0000000000000000"><mml:mi>k</mml:mi></mml:math></inline-formula> are normally distributed with mean <inline-formula id="ilml222-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math222-0000000000000000"><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math></inline-formula> and variance <inline-formula id="ilml223-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math223-0000000000000000"><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula>, <inline-formula id="ilml224-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math224-0000000000000000"><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>. First of all, to get a clear cut idea about the effective allocation proportion, that is proportion of allocation together with the variability, we provide a boxplot (see Figure 1) of the simulated proportion of allocation to treatment 1 for fixed difference in treatment effectiveness and varying response variability. For the plot, we take <inline-formula id="ilml225-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math225-0000000000000000"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>90</mml:mn></mml:mrow></mml:math></inline-formula> and generate responses for treatment 2 from a normal distribution with mean and variance both unity and those for treatment 1 are generated from a normal distribution with mean 1.50 but with varying <inline-formula id="ilml226-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math226-0000000000000000"><mml:mrow><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mo>,</mml:mo><mml:mn>1.0</mml:mn><mml:mo>,</mml:mo><mml:mn>2.0</mml:mn></mml:mrow></mml:math></inline-formula>. For the purpose of comparison we consider the following allocation rules:</p>
<list list-type="unorder" id="list2-0000000000000000">
<list-item><p>Equal allocation Rule (Denoted by A);</p></list-item>
<list-item><p>Ignoring the covariate, the allocation procedure of Bandyopadhyay and Biswas<sup><xref ref-type="bibr" rid="bibr60-0000000000000000">60</xref></sup> (Denoted by B);</p></list-item>
<list-item><p>Continuous drop-the-loser allocation<sup><xref ref-type="bibr" rid="bibr31-0000000000000000">31</xref></sup> (Denoted by C);</p></list-item>
<list-item><p>Ignoring the covariate, the allocation procedure of Biswas and Mandal<sup><xref ref-type="bibr" rid="bibr44-0000000000000000">44</xref></sup> (Denoted by D);</p></list-item>
<list-item><p>The Ethical-cum-Optimal allocation<sup><xref ref-type="bibr" rid="bibr39-0000000000000000">39</xref></sup> (Denoted by E);</p></list-item>
</list>
<p>together with <inline-formula id="ilml227-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math227-0000000000000000"><mml:mrow><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> and sequentially estimated <inline-formula id="ilml228-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math228-0000000000000000"><mml:mrow><mml:msup><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula>.</p>
<fig id="fig1-0000000000000000" position="float">
<label>Figure 1.</label>
<caption><p>Boxplot of the observed proportion of allocation to treatment 1 (denoted by <inline-formula id="ilml229-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math229-0000000000000000"><mml:mrow><mml:mi>P</mml:mi><mml:msub><mml:mi>A</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>).</p></caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_0000000000000000-fig1.tif"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_0000000000000000-fig2.tif"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_0000000000000000-fig3.tif"/>
</fig>
<p>Moreover to compare the statistical gain, we consider testing <inline-formula id="ilml230-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math230-0000000000000000"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:math></inline-formula> against <inline-formula id="ilml231-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math231-0000000000000000"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>1.50</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>1.0</mml:mn></mml:mrow></mml:math></inline-formula> and determine the sample size to attain 80% power for different values of <inline-formula id="ilml232-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math232-0000000000000000"><mml:msup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula>. The test is based on the estimated standardized treatment difference and a larger absolute value indicates rejection of the null hypothesis. The required sample sizes are reported in</p>
<table-wrap id="table1-0000000000000000" position="float"> <label>Table 1.</label> <caption><p>Trial size to ensure 80% power</p></caption> <alternatives> <graphic specific-use="table1-0000000000000000" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_0000000000000000table1.tif"/> <table> <thead align="left" valign="top"> <tr> <th>Allocation</th> <th><inline-formula id="ilml233-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math233-0000000000000000"><mml:mrow><mml:msup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mrow></mml:math></inline-formula></th> <th><inline-formula id="ilml234-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math234-0000000000000000"><mml:mrow><mml:msup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula></th> <th><inline-formula id="ilml235-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math235-0000000000000000"><mml:mrow><mml:msup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula></th> </tr> <tr> <th>Designs</th> <th/> <th/> <th/> </tr> </thead> <tbody align="left" valign="top"> <tr> <td>A</td> <td>96</td> <td>121</td> <td>182</td> </tr> <tr> <td>B</td> <td>111</td> <td>138</td> <td>193</td> </tr> <tr> <td>C</td> <td>102</td> <td>134</td> <td>194</td> </tr> <tr> <td>D</td> <td>99</td> <td>130</td> <td>191</td> </tr> <tr> <td>E</td> <td>126</td> <td>148</td> <td>203</td> </tr> </tbody> </table> </alternatives> </table-wrap>
<p><bold>Remarks:</bold> A close examination of the plot reveals that rules B and E assign the highest fraction to the better treatment (treatment 1 in this case) but with considerably larger variability irrespective of the choice of <inline-formula id="ilml236-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math236-0000000000000000"><mml:mi>&#x3C3;</mml:mi></mml:math></inline-formula>. Among the response-adaptive competitors, the lowest treatment variability is provided by allocation C though equal allocation provides the lowest variability among all the competitors. Moreover, from Table 1 we observe that equal allocation needs the lowest number observations to attain 80% power whatever be the value of the response variability. Among the response-adaptive procedures, procedure D ensured the desired level of power with minimum recruitment. A lower trial size, in fact, implies less allocation to the inferior treatment and hence is more ethical. Thus, allocation D seemed to be ethically satisfactory, of course, ensuring a specified statistical precision.</p>
</sec>
<sec id="sec23-0000000000000000">
<title>Redesigning a real clinical trials</title>
<p>Despite the attractive property of assigning larger number of subjects to the better treatment in course of the trial, only a few real response-adaptive trials , namely, the Fluoxetine trial<sup><xref ref-type="bibr" rid="bibr22-0000000000000000">22</xref></sup>, the trial reported by Rout et al.<sup><xref ref-type="bibr" rid="bibr78-0000000000000000">78</xref></sup> and the PEMF trial<sup><xref ref-type="bibr" rid="bibr79-0000000000000000">79</xref>,<xref ref-type="bibr" rid="bibr80-0000000000000000">80</xref></sup>, are available in literature. But in all these trials , the response variable is binary/categorical and so far as our knowledge goes, no response-adaptive trial with continuous response variable have been reported. However, the response variable in the Fluoxetine trial though measured in a 53 point ordinal scale is considered continuous by several authors<sup><xref ref-type="bibr" rid="bibr58-0000000000000000">58</xref></sup>. Now, for the purpose of illustration, we consider the randomized, placebo-controlled clinical trial conducted by Dworkin et al.<sup><xref ref-type="bibr" rid="bibr23-0000000000000000">23</xref></sup> with an objective to evaluate the efficacy and safety of <italic>Pregabalin</italic> in the treatment of postherpetic neuralgia (PHN). There were <inline-formula id="ilml237-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math237-0000000000000000"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>173</mml:mn></mml:mrow></mml:math></inline-formula> patients of which 84 received the standard therapy placebo (Treatment 1) and 89 were randomized to <italic>Pregabalin</italic> (Treatment 2). The primary efficacy measure was the mean of the last 7 daily pain ratings, as maintained by patients in a daily diary using the 11 point numerical pain rating scale (<inline-formula id="ilml238-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math238-0000000000000000"><mml:mrow><mml:mn>0</mml:mn><mml:mo>=</mml:mo></mml:mrow></mml:math></inline-formula> no pain, <inline-formula id="ilml239-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math239-0000000000000000"><mml:mrow><mml:mn>10</mml:mn><mml:mo>=</mml:mo></mml:mrow></mml:math></inline-formula> worst possible pain) and, therefore, a lower score (response in this case) indicates a favourable situation. After the 8 week duration of the trial, it was observed that <italic>Pregabalin</italic>-treated patients experienced a higher decrease in pain score than patients treated with placebo. We assume normality for the response variable and use the final mean scores as the true values and redesign the clinical trial with 10,000 repetitions of a response-adaptive trial recruiting <inline-formula id="ilml240-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math240-0000000000000000"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>173</mml:mn></mml:mrow></mml:math></inline-formula> patients following some response adaptive allocation procedure. Responses are generated from a normal distribution with mean <inline-formula id="ilml241-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math241-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>3.60</mml:mn></mml:mrow></mml:math></inline-formula> and variance <inline-formula id="ilml242-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math242-0000000000000000"><mml:mrow><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mn>2.25</mml:mn><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> for <italic>Pregabalin</italic> and with mean <inline-formula id="ilml243-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math243-0000000000000000"><mml:mrow><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>5.29</mml:mn></mml:mrow></mml:math></inline-formula> and variance <inline-formula id="ilml244-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math244-0000000000000000"><mml:mrow><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mn>2.20</mml:mn><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> for placebo. We consider the allocation procedures A, B, C, D and E stated above, and update the allocation probabilities for every incoming subject. Here <inline-formula id="ilml245-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math245-0000000000000000"><mml:msup><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula> is taken as earlier, the sequentially estimated <inline-formula id="ilml246-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math246-0000000000000000"><mml:mrow><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>&#x3C3;</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> with fixed <inline-formula id="ilml247-0000000000000000"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math247-0000000000000000"><mml:mrow><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false" form="prefix">(</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x3BC;</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false" form="postfix">)</mml:mo><mml:mi>/</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>. The behaviour of the number of allocations to <italic>Pregabalin</italic> and its variability is captured in the boxplot given in Figure 2 where the figures for rule A correspond to the procedure actually adopted in the original trial. However, the optimal rule of Zhang and Rosenberger<sup><xref ref-type="bibr" rid="bibr24-0000000000000000">24</xref></sup> is left out of consideration because this very procedure crashes whenever the estimated mean becomes negative. In fact, for the assumed normality, the probability of getting a negative response is at least 1%. For further details, the interested reader is referred to the work of Biswas, Bhattacharya and Zhang<sup><xref ref-type="bibr" rid="bibr42-0000000000000000">42</xref></sup> . <bold>Remarks:</bold> As expected, each of the response adaptive procedures resulted in more assignments to the better treatment as compared to the randomization actually followed in the trial. The assignment numbers for the procedures B and E are higher than those of the procedures C and D but the corresponding variabilities are lower for the procedures C and D. However, the expected number of allocations to <italic>Pregabalin</italic> are always higher for each of the response-adaptive procedures than the equal allocation procedure. Thus we conclude that had we used the response-adaptive alternatives, a considerably excess number of patients would have received the better treatment (<italic>Pregabalin</italic>) as compared to the actual trial.</p>
</sec>
</sec>
<sec id="sec24-0000000000000000">
<title>Discussion and Recommendation</title>
<p>In the current work we have reviewed various response-adaptive allocations when the treatment outcome is continuous. The presence of covariate information and possibility of multiple treatments are also considered. Other issues like optimality of the allocation and delay in responses are also addressed in this review. In addition, an investigation of the relative performance of few response-adaptive procedures within the framework of real clinical trials is also provided. However, adaptive randomization has disadvantages that must be considered together with the potential benefits<sup><xref ref-type="bibr" rid="bibr81-0000000000000000">81</xref>,<xref ref-type="bibr" rid="bibr82-0000000000000000">82</xref></sup>. The main concern is security because adaptive randomization requires continuous modifications of the allocation probabilities and hence there may be a leakage of information outside the sphere of confidentiality and this may affect the accrual of the patients. The possibility of information leakage can limit the credibility of a phase III trial. Again adaptive trials are based on getting outcome data into a central database while patients are being accrued and observed. But such an operation is not standard for clinical research organizations and hence there is a possibility of error. In addition, there is a negative aspect specific to any two-armed response adaptive randomization. In a two treatment( experimental and control) trial, if the experimental arm performs relatively poorly, then it will be little used. Naturally such an allocation is unlikely to be sponsored by pharmaceutical company because the company may end up funding a trial in which only a few number of the patients are actually assigned to their drug. However, given the ethical as well as inferential ability of the response-adaptive allocation, we hope the current review not only increase the interest in such allocations but also help the clinical practitioners in selecting the appropriate design for expedite the application in real clinical trials.
</p>

</sec>
</body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors wish to thank the referee for careful reading and suggestions which led to an improvement over an earlier version of the manuscript.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-0000000000000000">
        <label>1</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connor</surname><given-names> EM</given-names></name><name><surname>Sperling</surname><given-names> RS</given-names></name><name><surname>Gelber</surname><given-names> R</given-names></name><etal/></person-group>.<article-title>Reduction of maternal-infant transmission of human immunodeficiency virus of type 1 with zidovudine treatment.</article-title>.<source>New England Journal of Medicine</source><year>1994</year>;<volume>331</volume>:<fpage>1173</fpage>&#x2013;<lpage>1180</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr2-0000000000000000">
        <label>2</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zelen</surname><given-names> M</given-names></name><name><surname>Wei</surname><given-names> LJ</given-names></name></person-group><article-title> Foreword</article-title>. In:<person-group person-group-type="editor"><name><surname>Flournoy</surname><given-names> N</given-names></name><name><surname>Rosenberger</surname><given-names> WF</given-names></name></person-group>(eds).<source>Adaptive designs.</source>,<publisher-loc>  Hay ward, CA</publisher-loc>:<publisher-name> IMS</publisher-name>,<year> 1995</year>, </mixed-citation>
      </ref>
      <ref id="bibr3-0000000000000000">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names> Q</given-names></name><name><surname>Wei</surname><given-names> LJ</given-names></name></person-group>.<article-title>Play the winner for phase II/III
clinical trials.</article-title>.<source>Statistics in Medicine</source><year>1996</year>;<volume>15</volume>:<fpage>2413</fpage>&#x2013;<lpage>2423</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr4-0000000000000000">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names> LJ</given-names></name><name><surname>Durham</surname><given-names> S</given-names></name></person-group>.<article-title>The randomized play-the-winner rule in medical trials.</article-title>.<source>Journal of the American Statistical Association</source><year>1978</year>;<volume>73</volume>:<fpage>840</fpage>&#x2013;<lpage>843</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr5-0000000000000000">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dragalin</surname><given-names> V</given-names></name></person-group>.<article-title>Adaptive designs: terminology and classifications.</article-title>.<source>Drug Information Journal</source><year>2006</year>;<volume>40</volume>:<fpage>425</fpage>&#x2013;<lpage>435</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr6-0000000000000000">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names> WR</given-names></name></person-group>.<article-title>On the likelihood that one unknown probability exceeds another in the view of the evidence of the two samples.</article-title>.<source>Biometrika</source><year>1933</year>;<volume>25</volume>:<fpage>275</fpage>&#x2013;<lpage>294</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr7-0000000000000000">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names> H</given-names></name></person-group>.<article-title>Some aspects of the sequential design of experiments.</article-title>.<source>Bulletin of American Mathematical Society</source><year>1952</year>;<volume>58</volume>:<fpage>527</fpage>&#x2013;<lpage>535</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr8-0000000000000000">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anscombe</surname><given-names> FJ</given-names></name></person-group>.<article-title>Sequential medical trials.</article-title>.<source>Journal of the American Statistical Association</source><year>1963</year>;<volume>58</volume>:<fpage>365</fpage>&#x2013;<lpage>384</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr-0000000000000000">
        <label/>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname/><given-names/></name></person-group>.</mixed-citation>
      </ref>
      <ref id="bibr10-0000000000000000">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberger</surname><given-names> WF</given-names></name><name><surname>Lachin</surname><given-names> JM</given-names></name></person-group>.<article-title>The use of response-adaptive designs in clinical trials.</article-title>.<source>Controlled Clinical Trials</source><year>1993</year>;<volume>14</volume>:<fpage>471</fpage>&#x2013;<lpage>484</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr11-0000000000000000">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberger</surname><given-names> WF</given-names></name></person-group>.<article-title>New directions in adaptive designs.</article-title>.<source>Statistical Science</source><year>1996</year>;<volume>11</volume>:<fpage>137</fpage>&#x2013;<lpage>149</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr12-0000000000000000">
        <label>12</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rosenberger</surname><given-names> WF</given-names></name><name><surname>Lachin</surname><given-names> JL</given-names></name></person-group>.<source>Randomisation in clinical trials: Theory and practice.</source>,<publisher-loc> New York, NY</publisher-loc>:<publisher-name> Wiley</publisher-name>,<year> 2002</year>, </mixed-citation>
      </ref>
      <ref id="bibr13-0000000000000000">
        <label>13</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Chow</surname><given-names> Sh-Ch</given-names></name><name><surname>Chang</surname><given-names> M</given-names></name></person-group>.<source>Adaptive design methods in clinical trials.</source>,<publisher-loc> Boca Raton</publisher-loc>:<publisher-name> Chapman Hall CRC</publisher-name>,<year> 2006</year>, </mixed-citation>
      </ref>
      <ref id="bibr-0000000000000000">
        <label/>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname/><given-names/></name></person-group>.</mixed-citation>
      </ref>
      <ref id="bibr15-0000000000000000">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelen</surname><given-names> M</given-names></name></person-group>.<article-title>Play the winner rule and the controlled clinical trial.</article-title>.<source>Journal of the American Statistical Association</source><year>1969</year>;<volume>64</volume>:<fpage>131</fpage>&#x2013;<lpage>146</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr16-0000000000000000">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durham</surname><given-names> SD</given-names></name><name><surname>Flournoy</surname><given-names> N</given-names></name><name><surname>Li</surname><given-names> W</given-names></name></person-group>.<article-title>Sequential designs for maximizing the probability of a favorable response.</article-title>.<source>Canadian Journal of Statistics</source><year>1998</year>;<volume>3</volume>:<fpage>479</fpage>&#x2013;<lpage>495</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr17-0000000000000000">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanova</surname><given-names> A</given-names></name></person-group>.<article-title>A play-the-winner type urn model with reduced variability.</article-title>.<source>Metrika</source><year>2003</year>;<volume>58</volume>:<fpage>1</fpage>&#x2013;<lpage>13</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr18-0000000000000000">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names> LX</given-names></name><name><surname>Chan</surname><given-names> WS</given-names></name><name><surname>Cheung</surname><given-names> SH</given-names></name><etal/></person-group>.<article-title>A generalized drop-the-loser urn for clinical trials with delayed responses.</article-title>.<source>Statistica Sinica</source><year>2007</year>;<volume>17</volume>:<fpage>387</fpage>&#x2013;<lpage>409</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr19-0000000000000000">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names> A</given-names></name></person-group>.<article-title>Adaptive designs in phase III clinical trials: controversies and progress.</article-title>.<source>Statistical Methods in Medical Research</source><year>2001</year>;<volume>10</volume>:<fpage>353</fpage>&#x2013;<lpage>364</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr20-0000000000000000">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names> TW</given-names></name><name><surname>Lacourci$\grave{e}$re</surname><given-names> Y</given-names></name><name><surname>Barnes</surname><given-names> CC</given-names></name></person-group>.<article-title>The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring.</article-title>.<source>Canadian Medical Association Journal</source><year>1998</year>;<volume>8</volume>:<fpage>469</fpage>&#x2013;<lpage>476</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr21-0000000000000000">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loo</surname><given-names> C</given-names></name><name><surname>Mitchell</surname><given-names> P</given-names></name><name><surname>Sachdev</surname><given-names> P</given-names></name><etal/></person-group>.<article-title>Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression.</article-title>.<source>American Journal of Psychiatry</source><year>1999</year>;<volume>156</volume>:<fpage>946</fpage>&#x2013;<lpage>948</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr22-0000000000000000">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names> RN</given-names></name><name><surname>Faries</surname><given-names> DE</given-names></name><name><surname>Andersen</surname><given-names> JS</given-names></name><etal/></person-group>.<article-title>A case study of an adaptive clinical trial in the treatment of out-patients with depressive disorder.</article-title>.<source>Journal of the American Statistical Association</source><year>1994</year>;<volume>89</volume>:<fpage>768</fpage>&#x2013;<lpage>776</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr23-0000000000000000">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dworkin</surname><given-names> RH</given-names></name><name><surname>Corbin</surname><given-names> AE</given-names></name><name><surname>Young</surname><given-names> JP</given-names></name><etal/></person-group>.<article-title>Pregabalin for the treatment of  postherpetic neuralgia. A randomized, placebo-controlled trial.</article-title>.<source>Neurology</source><year>2003</year>;<volume>60</volume>:<fpage>1274</fpage>&#x2013;<lpage>1283</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr24-0000000000000000">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names> LX</given-names></name><name><surname>Rosenberger</surname><given-names> WF</given-names></name></person-group>.<article-title>Response-adaptive randomization for clinical trials with continuous outcomes.</article-title>.<source>Biometrics</source><year>2006</year>;<volume>62</volume>:<fpage>562</fpage>&#x2013;<lpage>569</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr25-0000000000000000">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhyay</surname><given-names> U</given-names></name><name><surname>Biswas A</surname><given-names/></name><name><surname>Bhattacharya</surname><given-names> R</given-names></name></person-group>.<article-title>Kernel based response-adaptive design for continuous responses.</article-title>.<source>Communications in Statistics: Theory and Methods</source><year>2008</year>;<volume>38</volume>:<fpage>2691</fpage>&#x2013;<lpage>2705</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr26-0000000000000000">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhyay</surname><given-names> U</given-names></name><name><surname>Biswas A</surname><given-names/></name><name><surname>Bhattacharya</surname><given-names> R</given-names></name></person-group>.<article-title>A new response-adaptive design for continuous treatment responses for phase III clinical trials.</article-title>.<source>Journal of Statistical Planning and Inference</source><year>2011</year>;<volume>141</volume>:<fpage>2256</fpage>&#x2013;<lpage>2265</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr27-0000000000000000">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names> X</given-names></name><name><surname>Shen</surname><given-names> Z</given-names></name><name><surname>Chen</surname><given-names> Y</given-names></name><etal/></person-group>.<article-title>Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns.</article-title>.<source>Lancet</source><year>1998</year>;<volume>352</volume>:<fpage>1661</fpage>&#x2013;<lpage>1664</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr28-0000000000000000">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhyay</surname><given-names> U</given-names></name><name><surname>Biswas</surname><given-names> A</given-names></name></person-group>.<article-title>Delayed response in randomized play-the-winner rule: a  decision  theoretic outlook.</article-title>.<source>Calcutta Statistical Association Bulletin</source><year>1996</year>;<volume>46</volume>:<fpage>69</fpage>&#x2013;<lpage>88</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr29-0000000000000000">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberger</surname><given-names> WF</given-names></name></person-group>.<article-title>Asymptotic inference with response-adaptive treatment allocation designs.</article-title>.<source>Annals of Statistics</source><year>1993</year>;<volume>21</volume>:<fpage>2098</fpage>&#x2013;<lpage>2107</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr30-0000000000000000">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberger</surname><given-names> WF</given-names></name><name><surname>Seshaiyer</surname><given-names> P</given-names></name></person-group>.<article-title>Adaptive survival trials.</article-title>.<source>Journal of Biopharmaceutical Statistics</source><year>1997</year>;<volume>7</volume>:<fpage>617</fpage>&#x2013;<lpage>624</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr31-0000000000000000">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanova</surname><given-names> A</given-names></name><name><surname>Biswas</surname><given-names> A</given-names></name><name><surname>Lurie</surname><given-names> H</given-names></name></person-group>.<article-title>Response adaptive designs for continuous outcomes.</article-title>.<source>Journal of the Statistical Planning and Inference</source><year>2006</year>;<volume>136</volume>:<fpage>1845</fpage>&#x2013;<lpage>1852</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr32-0000000000000000">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas A</surname><given-names/></name><name><surname>Bhattacharya</surname><given-names> R</given-names></name></person-group>.<article-title>Optimal response-adaptive designs for normal responses.</article-title>.<source>Biometrical Journal</source><year>2009</year>;<volume>51</volume>:<fpage>193</fpage>&#x2013;<lpage>202</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr33-0000000000000000">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhyay</surname><given-names> U</given-names></name><name><surname>Biswas</surname><given-names> A</given-names></name></person-group>.<article-title>An adaptive allocation for continuous response using Wilcoxon-Mann-Whitney score.</article-title>.<source>Journal of Statistical Planning and Inference</source><year>2004</year>;<volume>123</volume>:<fpage>207</fpage>&#x2013;<lpage>224</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr34-0000000000000000">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisele</surname><given-names> J</given-names></name></person-group>.<article-title>The doubly adaptive biased coin design for sequential clinical trials.</article-title>.<source>Journal of Statistical Planning and Inference</source><year>1994</year>;<volume>38</volume>:<fpage>249</fpage>&#x2013;<lpage>262</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr35-0000000000000000">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eisele</surname><given-names> J</given-names></name><name><surname>Woodroofe</surname><given-names> M</given-names></name></person-group>.<article-title>Central limit theorems for doubly adaptive biased coin designs.</article-title>.<source>Annals of Statistics</source><year>1995</year>;<volume>23</volume>:<fpage>234</fpage>&#x2013;<lpage>254</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr36-0000000000000000">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names> F</given-names></name><name><surname>Zhang</surname><given-names> LX</given-names></name></person-group>.<article-title>Asymptotic properties of doubly adaptive biased coin design for multi-treatment clinical trials.</article-title>.<source>Annals of Statistics</source><year>2004</year>;<volume>32</volume>:<fpage>268</fpage>&#x2013;<lpage>301</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr37-0000000000000000">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melfi</surname><given-names> VF</given-names></name><name><surname>Page</surname><given-names> C</given-names></name><name><surname>Geraldes</surname><given-names> M</given-names></name></person-group>.<article-title>An adaptive randomized design with application to estimation.</article-title>.<source>Canadian Journal of Statistics</source><year>2001</year>;<volume>29</volume>:<fpage>107</fpage>&#x2013;<lpage>116</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr38-0000000000000000">
        <label>38</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberger</surname><given-names> WF</given-names></name><name><surname>Stallard</surname><given-names> N</given-names></name><name><surname>Ivanova</surname><given-names> A</given-names></name><etal/></person-group>.<article-title>Optimal adaptive designs for binary response trials.</article-title>.<source>Biometrics</source><year>2001</year>;<volume>57</volume>:<fpage>173</fpage>&#x2013;<lpage>177</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr39-0000000000000000">
        <label>39</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhyay</surname><given-names> U</given-names></name><name><surname>Bhattacharya</surname><given-names> R</given-names></name></person-group>.<article-title>Adaptive Allocation and Failure Saving in Randomised Clinical Trials.</article-title>.<source>Journal of Biopharmaceutical Statistics</source><year>2006</year>;<volume>16</volume>:<fpage>1</fpage>&#x2013;<lpage>13</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr40-0000000000000000">
        <label>40</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imrey</surname><given-names> PB</given-names></name><name><surname>Kingman</surname><given-names> A</given-names></name></person-group>.<article-title>Analysis of clinical trials involving non-cavitated caries lesions.</article-title>.<source>Journal of Dental Research</source><year>2004</year>;<volume>83</volume>:</mixed-citation>
      </ref>
      <ref id="bibr41-0000000000000000">
        <label>41</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jennison</surname><given-names> C</given-names></name><name><surname>Turnbull</surname><given-names> BW</given-names></name></person-group>.<source>Group sequential methods with applications to clinical trials.</source>,<publisher-loc> Boca Raton, Florida</publisher-loc>:<publisher-name> Chapman and
Hall/CRC</publisher-name>,<year> 2000</year>, </mixed-citation>
      </ref>
      <ref id="bibr42-0000000000000000">
        <label>42</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hardwick</surname><given-names> J</given-names></name><name><surname>Stout</surname><given-names> QF</given-names></name></person-group><article-title>  Flexible algorithms for creating and analyzing adaptive sampling procedures</article-title>. In:<person-group person-group-type="editor"><name><surname>Flournoy</surname><given-names> N</given-names></name><name><surname>Rosenberger</surname><given-names> WF</given-names></name><name><surname>Wong</surname><given-names> WK</given-names></name></person-group>(eds).<source>New developments and applications in experimental design.</source>,<publisher-loc> Hayward</publisher-loc>:<publisher-name> Institute of Mathematical Statistics</publisher-name>,<year> 1998</year>, pp.<fpage>91</fpage>&#x2013;<lpage>105</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr43-0000000000000000">
        <label>43</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names> A</given-names></name><name><surname>Bhattacharya</surname><given-names> R</given-names></name><name><surname>Zhang</surname><given-names> L</given-names></name></person-group>.<article-title>Optimal Response-Adaptive Designs for continuous responses in Phase III  trials.</article-title>.<source>Biometrical Journal</source><year>2007</year>;<volume>49</volume>:<fpage>928</fpage>&#x2013;<lpage>940</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr44-0000000000000000">
        <label>44</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names> A</given-names></name><name><surname>Mandal</surname><given-names> S</given-names></name></person-group><article-title> Optimal adaptive designs in
phase III clinical trials for continuous responses with covariates</article-title>. In:<person-group person-group-type="editor"><name><surname>Bucchianico</surname><given-names> ADi</given-names></name><name><surname>L$\ddot{a}$uter</surname><given-names> H</given-names></name><name><surname>Wynn</surname><given-names> HP</given-names></name></person-group>(eds).<source>moDa 7 - Advances in model-oriented design and analysis.</source>,<publisher-loc> Heidelberg</publisher-loc>:<publisher-name> Physica-Verlag</publisher-name>,<year> 2004</year>, pp.<fpage>51</fpage>&#x2013;<lpage>58</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr45-0000000000000000">
        <label>45</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhyay</surname><given-names> U</given-names></name><name><surname>Bhattacharya</surname><given-names> R</given-names></name></person-group>.<article-title>Response adaptive procedures with dual optimality.</article-title>.<source>Statistica Neerlandica</source><year>2009</year>;<volume>63</volume>:<fpage>353</fpage>&#x2013;<lpage>367</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr46-0000000000000000">
        <label>46</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names> A</given-names></name><name><surname>Bhattacharya</surname><given-names> R</given-names></name></person-group>.<article-title>An optimal response-adaptive design with dual constraints.</article-title>.<source>Statistics \&amp; Probability Letters</source><year>2010</year>;<volume>80</volume>:<fpage>177</fpage>&#x2013;<lpage>185</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr47-0000000000000000">
        <label>47</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antognini</surname><given-names> AB</given-names></name><name><surname>Giovagnoli</surname><given-names> A</given-names></name></person-group>.<article-title>On the large sample optimality of sequential designs for comparing two or more treatments.</article-title>.<source>Sequential Analysis</source><year>2005</year>;<volume>24</volume>:<fpage>205</fpage>&#x2013;<lpage>217</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr48-0000000000000000">
        <label>48</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Silvey</surname><given-names> SD</given-names></name></person-group>.<source>Optimum design.</source>,<publisher-loc> London</publisher-loc>:<publisher-name> Chapman and Hall</publisher-name>,<year> 1980</year>, </mixed-citation>
      </ref>
      <ref id="bibr49-0000000000000000">
        <label>49</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names> L</given-names></name><name><surname>Rosenberger</surname><given-names> WF</given-names></name></person-group>.<article-title>Response-adaptive randomization for survival trials: The parametric approach.</article-title>.<source>Journal of the Royal Statistical Society Series C</source><year>2007</year>;<volume>34</volume>:<fpage>562</fpage>&#x2013;<lpage>569</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr50-0000000000000000">
        <label>50</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tymofyeyev</surname><given-names> Y</given-names></name><name><surname>Rosenberger</surname><given-names> WF</given-names></name><name><surname>Hu</surname><given-names> F</given-names></name></person-group>.<article-title>Implementing optimal allocation in sequential binary response experiments.</article-title>.<source>Journal of American Statistical Association</source><year>2007</year>;<volume>102</volume>:<fpage>224</fpage>&#x2013;<lpage>234</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr51-0000000000000000">
        <label>51</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names> H</given-names></name><name><surname>Hu</surname><given-names> F</given-names></name></person-group>.<article-title>Implementing optimal allocation in sequential continuous response experiments.</article-title>.<source>Journal of  Statistical Planning and  Inference</source><year>2009</year>;<volume>139</volume>:<fpage>2420</fpage>&#x2013;<lpage>2430</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr52-0000000000000000">
        <label>52</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names> A</given-names></name><name><surname>Mandal</surname><given-names> S</given-names></name><name><surname>Bhattacharya</surname><given-names> R</given-names></name></person-group>.<article-title>Multi-treatment optimal response-adaptive designs for phase III clinical trials.</article-title>.<source>Journal of the Korean Statistical Society</source><year>2010</year>;<volume>40</volume>:<fpage>33</fpage>&#x2013;<lpage>44</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr-0000000000000000">
        <label/>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname/><given-names/></name></person-group>.</mixed-citation>
      </ref>
      <ref id="bibr54-0000000000000000">
        <label>54</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begg</surname><given-names> CB</given-names></name><name><surname>Iglewicz</surname><given-names> B</given-names></name></person-group>.<article-title>A treatment allocation
procedure for sequential clinical trials.</article-title>.<source>Biometrics</source><year>1980</year>;<volume>36</volume>:<fpage>81</fpage>&#x2013;<lpage>90</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr55-0000000000000000">
        <label>55</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names> AC</given-names></name></person-group>.<article-title>Optimum biased coin designs for sequential clinical trials with prognostic factors.</article-title>.<source>Biometrika</source><year>1982</year>;<volume>69</volume>:<fpage>61</fpage>&#x2013;<lpage>67</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr56-0000000000000000">
        <label>56</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names> AC</given-names></name></person-group>.<article-title>Optimum biased-coin designs for sequential treatment allocation with covariate information.</article-title>.<source>Statistics in Medicine</source><year>1999</year>;<volume>18</volume>:<fpage>1741</fpage>&#x2013;<lpage>1752</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr57-0000000000000000">
        <label>57</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names> AC</given-names></name></person-group>.<article-title>Bayesian and other biased-coin designs for sequential clinical trials.</article-title>.<source>Tatra Mountains Mathematical Publications</source><year>1999</year>;<volume>17</volume>:<fpage>133</fpage>&#x2013;<lpage>139</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr58-0000000000000000">
        <label>58</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names> AC</given-names></name><name><surname>Biswas</surname><given-names> A</given-names></name></person-group>.<article-title>Bayesian adaptive biased-coin designs for clinical trials with normal responses.</article-title>.<source>Biometrics</source><year>2005</year>;<volume>61</volume>:<fpage>118</fpage>&#x2013;<lpage>125</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr59-0000000000000000">
        <label>59</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names> WK</given-names></name><name><surname>Zhu</surname><given-names> W</given-names></name></person-group>.<article-title>Optimum treatment allocation rules under a variance heterogeneity model.</article-title>.<source>Statistics in Medicine</source><year>2008</year>;<volume>27</volume>:<fpage>4581</fpage>&#x2013;<lpage>4595</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr60-0000000000000000">
        <label>60</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhyay</surname><given-names> U</given-names></name><name><surname>Biswas</surname><given-names> A</given-names></name></person-group>.<article-title>Adaptive designs for normal responses with prognostic factors.</article-title>.<source>Biometrika</source><year>2001</year>;<volume>88</volume>:<fpage>409</fpage>&#x2013;<lpage>419</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr61-0000000000000000">
        <label>61</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names> A</given-names></name><name><surname>Coad</surname><given-names> DS</given-names></name></person-group>.<article-title>A general multi-treatment adaptive design for multivariate responses.</article-title>.<source>Sequential Analysis</source><year>2005</year>;<volume>24</volume>:<fpage>139</fpage>&#x2013;<lpage>158</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr62-0000000000000000">
        <label>62</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names> A</given-names></name><name><surname>Huang</surname><given-names> HH</given-names></name><name><surname>Huang</surname><given-names> WT</given-names></name></person-group>.<article-title>Covariate-adjusted adaptive designs for continuous responses in a Phase III clinical trial:
Recommendation for practice .</article-title>.<source>Journal of Biopharmaceutical
Statistics</source><year>2006</year>;<volume>16</volume>:<fpage>227</fpage>&#x2013;<lpage>239</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr63-0000000000000000">
        <label>63</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names> LX</given-names></name><name><surname>Hu</surname><given-names> F</given-names></name><name><surname>Cheung</surname><given-names> SH</given-names></name><etal/></person-group>.<article-title>Asymptotic properties of covariate-adjusted response-adaptive designs.</article-title>.<source>Annals of Statistics</source><year>2007</year>;<volume>35</volume>:<fpage>1166</fpage>&#x2013;<lpage>1182</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr64-0000000000000000">
        <label>64</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names> LX</given-names></name><name><surname>Hu</surname><given-names> F</given-names></name></person-group>.<article-title>A new family of covariate-adjusted response adaptive designs and their properties.</article-title>.<source>Applied Mathematics-A Journal Of Chinese Universities; Series B</source><year>2009</year>;<volume>24</volume>:<fpage>1</fpage>&#x2013;<lpage>13</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr65-0000000000000000">
        <label>65</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Antognini</surname><given-names> AB</given-names></name><name><surname>Zgoraiou</surname><given-names> M</given-names></name></person-group><article-title> Covariate adjusted designs for  combining efficiency, ethics and randomness in normal response trials</article-title>. In:<person-group person-group-type="editor"><name><surname>Giovagnoli</surname><given-names> A</given-names></name><name><surname>Atkinson</surname><given-names> AC</given-names></name><name><surname>Torsney</surname><given-names> B</given-names></name></person-group>(eds).<source>moDa 9 - Advances in model-oriented design and analysis.</source>,<publisher-loc> Berlin, Heidelberg</publisher-loc>:<publisher-name> Springer-Verlag</publisher-name>,<year> 2010</year>, pp.<fpage>17</fpage>&#x2013;<lpage>24</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr66-0000000000000000">
        <label>66</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names> LM</given-names></name><name><surname>Furberg</surname><given-names> CD</given-names></name><name><surname>DeMets</surname><given-names> DL</given-names></name></person-group>.<source>Fundamentals of clinical trials, Third Edition.</source>,<publisher-loc> New York, NY</publisher-loc>:<publisher-name> Springer-Verlag</publisher-name>,<year> 1998</year>, </mixed-citation>
      </ref>
      <ref id="bibr-0000000000000000">
        <label/>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname/><given-names/></name></person-group>.</mixed-citation>
      </ref>
      <ref id="bibr68-0000000000000000">
        <label>68</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names> A</given-names></name><name><surname>Angers</surname><given-names> JF</given-names></name></person-group>.<article-title>A Bayesian adaptive design in clinical trials for continuous responses.</article-title>.<source>Statistica Neerlandica</source><year>2002</year>;<volume>56</volume>:<fpage>400</fpage>&#x2013;<lpage>414</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr69-0000000000000000">
        <label>69</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names> F</given-names></name><name><surname>Rosenberger</surname><given-names> WF</given-names></name></person-group>.<article-title>Optimality, variability, power: Evaluating response adaptive randomization procedures for treatment comparisons.</article-title>.<source>Journal of American Statistical Association</source><year>2003</year>;<volume>98</volume>:<fpage>671</fpage>&#x2013;<lpage>678</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr70-0000000000000000">
        <label>70</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names> F</given-names></name><name><surname>Rosenberger</surname><given-names> WF</given-names></name><name><surname>Zhang</surname><given-names> L-X</given-names></name></person-group>.<article-title>Asymptotically best response-adaptive randomization procedures.</article-title>.<source>Journal of Statistical Planning and Inference</source><year>2006</year>;<volume>136</volume>:<fpage>1911</fpage>&#x2013;<lpage>1922</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr71-0000000000000000">
        <label>71</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names> F</given-names></name><name><surname>Zhang</surname><given-names> L-X</given-names></name><name><surname>He</surname><given-names> X</given-names></name></person-group>.<article-title>Efficient randomized-adaptive designs.</article-title>.<source>The Annals of Statistics</source><year>2009</year>;<volume>37</volume>:<fpage>2543</fpage>&#x2013;<lpage>2560</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr72-0000000000000000">
        <label>72</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efron</surname><given-names> B</given-names></name></person-group>.<article-title>Forcing a sequential experiment to be balanced.</article-title>.<source>Biometrika</source><year>1971</year>;<volume>58</volume>:<fpage>403</fpage>&#x2013;<lpage>417</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr73-0000000000000000">
        <label>73</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names> LJ</given-names></name></person-group>.<article-title>Exact two-sample permutation tests based on the randomized play-the-winner rule in medical trials.</article-title>.<source>Biometrika</source><year>1988</year>;<volume>75</volume>:<fpage>603</fpage>&#x2013;<lpage>606</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr74-0000000000000000">
        <label>74</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanova</surname><given-names> A</given-names></name><name><surname>Rosenberger</surname><given-names> WF</given-names></name></person-group>.<article-title>A comparison of urn designs for randomized clinical trials of $K&gt;2$ treatments.</article-title>.<source>Journal of Biopharmaceutical Statistics</source><year>2000</year>;<volume>10</volume>:<fpage>93</fpage>&#x2013;<lpage>107</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr75-0000000000000000">
        <label>75</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names> ZD</given-names></name><name><surname>Hu</surname><given-names> F</given-names></name><name><surname>Rosenberger</surname><given-names> WF</given-names></name></person-group>.<article-title>Asymptotic properties of adaptive designs for clinical trials with delayed response.</article-title>.<source>Annals of Statistics</source><year>2002</year>;<volume>30</volume>:<fpage>122</fpage>&#x2013;<lpage>129</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr76-0000000000000000">
        <label>76</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names> A</given-names></name></person-group>.<article-title>Generalized delayed response in randomized play-the-winner rule.</article-title>.<source>Communications in Statistics - Simulation and Computation</source><year>2003</year>;<volume>32</volume>:<fpage>259</fpage>&#x2013;<lpage>274</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr77-0000000000000000">
        <label>77</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names> F</given-names></name><name><surname>Zhang</surname><given-names> LX</given-names></name><name><surname>Cheung</surname><given-names> SH</given-names></name><etal/></person-group>.<article-title>Doubly adaptive biased coin designs with delayed responses.</article-title>.<source>The Canadian Journal of Statistics</source><year>2008</year>;<volume>36</volume>:<fpage>541</fpage>&#x2013;<lpage>559</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr78-0000000000000000">
        <label>78</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rout</surname><given-names> CC</given-names></name><name><surname>Rocke</surname><given-names> DA</given-names></name><name><surname>Levin</surname><given-names> J</given-names></name><etal/></person-group>.<article-title>A reevaluation of the role of crystalloid preload in the prevention of hypotension associated with spinal anesthesia for elective cesarean section.</article-title>.<source>Anesthesiology</source><year>1993</year>;<volume>79</volume>:<fpage>262</fpage>&#x2013;<lpage>269</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr79-0000000000000000">
        <label>79</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names> A</given-names></name><name><surname>Dewanji</surname><given-names> A</given-names></name></person-group>.<article-title>A Randomized longitudinal play-the-winner design for repeated binary data.</article-title>.<source>Australian and New Zealand Journal of Statistics</source><year>2004</year>;<volume>46</volume>:<fpage>675</fpage>&#x2013;<lpage>684</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr80-0000000000000000">
        <label>80</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names> A</given-names></name><name><surname>Dewanji</surname><given-names> A</given-names></name></person-group>.<article-title>Inference for a RPW-type clinical trial with repeated monitoring for the treatment of rheumatoid arthritis.</article-title>.<source>Biometrical Journal</source><year>2004</year>;<volume>46</volume>:<fpage>769</fpage>&#x2013;<lpage>779</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr81-0000000000000000">
        <label>81</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names> DA</given-names></name></person-group>.<article-title>Adaptive clinical trials: The promise and the caution.</article-title>.<source>Journal of  Clinical Oncology</source><year>2011</year>;<volume>29</volume>:<fpage>606</fpage>&#x2013;<lpage>609</lpage>.</mixed-citation>
      </ref>
      <ref id="bibr82-0000000000000000">
        <label>82</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korn</surname><given-names> EL</given-names></name><name><surname>Freidlin</surname><given-names> B</given-names></name></person-group>.<article-title>Outcome-adaptive randomization: Is it useful?</article-title>.<source>Journal of  Clinical Oncology</source><year>2011</year>;<volume>29</volume>:<fpage>771</fpage>&#x2013;<lpage>776</lpage>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
